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ABSTRACT 
 
Viral protein 35 (VP35), encoded by filoviruses, are multifunctional dsRNA 
binding proteins that play important roles in viral replication, innate immune evasion and 
pathogenesis. The multifunctional nature of these proteins also presents opportunities 
to develop countermeasures that target distinct functional regions. However, functional 
validation and the establishment of therapeutic approaches toward such multifunctional 
proteins, particularly for non-enzymatic targets, are often challenging. With the current 
lack of approved vaccines or therapeutic options available to target filoviral infections, 
work that lends itself to the development of such inhibitors will be instrumental in 
countering this highly pathogenic virus. Our previous work on filoviral VP35 proteins 
defined two highly conserved conserved basic patches, the first basic patch (FBP) and 
the central basic patch (CBP), located within the C-terminal dsRNA binding interferon 
(IFN) inhibitory domain (IID). This work went on to show that the CBP is important for 
VP35 mediated IFN antagonism, in part through its ability to bind dsRNA. The goal of 
my thesis work was to investigate the functional importance of the FBP through a 
combination of structural and biochemical studies, and validate VP35 as a potential 
therapeutic target. These efforts established that residues within the FBP are 
functionally distinct from the CBP, but are important for VP35 polymerase co-factor 
function. Although the exact role of these VP35 residues in replication is poorly defined, 
the replication defective FBP mutants lost their ability to interact with the viral 
nucleoprotein, indicating that the VP35 FBP provides critical contacts which establish 
the VP35-NP interaction. In order to therapeutically target these functional regions of 
xvi 
 
 
VP35 and validate VP35 as a potential and promising antiviral target, we targeted Ebola 
virus (EBOV) VP35 (eVP35) for aptamer selection using SELEX. Select aptamers, 
representing two distinct classes, were further characterized based on their interaction 
properties to eVP35 IID. These results revealed that the aptamers bind to distinct 
regions of eVP35 IID with high affinity (10-50 nM) and specificity. These aptamers can 
compete with dsRNA for binding to eVP35 and disrupt the eVP35-NP interaction. 
Consistent with the ability to antagonize eVP35-NP interaction, select aptamers can 
inhibit the function of the EBOV polymerase complex reconstituted by expression of 
select viral proteins. Taken together, our results serve as an initial step in enhancing our 
understanding of the protein-protein interactions that establish the EBOV polymerase 
complex, and support the identification of two aptamers that bind filoviral VP35 proteins 
with high affinity and specificity and have the capacity to potentially target filoviral VP35 
proteins as a therapeutic target.  
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CHAPTER 1.  INTRODUCTION 
 
1.1 Introduction 
 In order to protect against pathogens, host immune systems must recognize, 
counter, and purge themselves of foreign invaders. Distilled down to its most basic 
concept, the immune system must distinguish differences between self and non-self in 
order to effectively clear an infection. Many viral pathogens have co-evolved with their 
host organisms and developed ways to replicate and sustain themselves despite an 
onslaught of host immune defenses. Deconstructing the viral-host interface at a 
molecular level will be crucial to understanding of both host immunity and viral 
pathogenesis. Research designed to elucidate the intermolecular interactions between 
viral immunomodulatory proteins and host proteins will therefore be critical to the 
development of new and innovative therapeutic agents to counter viral infections. 
 The host immune system responds to pathogens through highly tailored, intricate 
pathways, which can integrate various signals and generate systematic cellular changes 
to counter and clear the invading pathogens. Host immune responses can be divided 
into two branches: innate and adaptive immunity, the latter which will not be discussed 
in the context of this thesis. Innate immunity provides the first line of defense, allowing 
the detection of a wide range of pathogens. The broad response elicited by the innate 
immune system is achieved through cellular surveillance proteins called pattern 
recognition receptors (PRRs) which recognize molecular markers characteristic to 
pathogens, termed pathogen-associated molecular patterns (PAMPs) (Akira et al. 2006) 
(Figure 1.1A). PRRs can be categorized into four classes: C-type lectin receptors 
(CLRs), Toll-like receptors (TLRs), NOD-like receptors (NLRs), and Retinoic acid-
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inducible gene I (RIG-I)-like receptors (RLRs) (Figure 1.1B). These PRRs are locatized 
to various cellular compartments, including the cell surface, the endosome, and the 
cytoplasm providing surveillance for a diverse range of PAMPs. Engagement of PAMPs 
by select PRRs results in signal transduction cascades which produce interferons, 
chemokines and cytokines, ultimately leading to the establishment of an inflamatory 
response, activation of adaptive immunity, and clearance of the pathogen. The 
pathways and signaling events involved in these processes are highly regulated with 
distinct and overlapping characteristics and varying degrees of cross-talk to provide the 
fullest protective coverage (Crozat et al. 2009).  
 Filoviruses potently antagonize the Type-I interferon pathway, in particularly 
RLR-dependent activation of IFN-β signaling (Figure 1.2). RLRs are PRRs localized to 
the cytoplasm that play a critical role in detecting viral PAMPs, especially those derived 
from RNA viruses. In an inactivated state, RLRs are found in an auto-inhibited 
conformation, but undergo conformational rearrangement upon association with viral 
RNA. The rearrangement allows their caspase activation and recruitment domains 
(CARDs) to interact with the CARD domains of the mitochondrial antiviral signaling 
(MAVS) protein, an essential mitochondrial anchored adapter protein in the Type-I IFN 
signaling cascade (Hou et al. 2011). Notably, both the RLRs and the TLRs signal 
through MAVS and therefore converge at this point. Association of the RLR and MAVS 
CARD domains activates the Type-I IFN response which mediates downstream 
signaling and leads to the phosphorylation and translocation of interferon regulatory 
transcription factors (IRF)-3/7 to the nucleus. IRF3/7 then promote the induction of 
Type-I IFNs (IFN-α and IFN-β). Interferons produced by an infected cell are secreted 
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and can act in an autocrine or paracrine fashion to activate the JAK/STAT pathway and 
promote the induction of a number of interferon stimulated genes, or ISGs, which work 
in concert to establish an antiviral state within the cell (Zuniga et al. 2007; Bonjardim et 
al. 2009).   
 The RLR family contains three proteins: RIG-I, melanoma differentiation 
associated gene 5 (MDA-5), and laboratory of genetics and physiology 2 (LGP-2) 
(Figure 1.3). Both RIG-I and MDA-5 have two N-terminal CARD domains, whereas 
LGP-2 has none (Fig 1.3A). The CARD domains are essential for RIG-I mediated 
signaling, and it has been shown that expression of the CARD domains alone results in 
constitutive activation of the Type-I signaling pathway (Yoneyama et al. 2004). Due to 
the lack of CARD domains in LGP-2, it has been speculated that LGP-2 serves as a 
negative regulator for RIG-I and MDA-5 (Fig 1.3B). However, a recent report by Satoh 
et al. (Satoh et al. 2010) suggests LGP-2 serves as an activator of RLR-dependent 
signaling. Though there have been a number of recent discoveries that have shaped 
our understanding of these RLRs, how these proteins are regulated and the exact role 
of LGP-2 remains poorly understood.  
 Recent structural work with both RIG-I and MDA-5 has provided much needed 
insight into the activation mechanism of RLRs, as well as clarified how RIG-I and MDA-
5 discriminate between their respective PAMPs (Kolakofsky et al. 2012; Leung et al. 
2012; Beckham et al. 2013; Feng et al. 2013; Wu et al. 2013). Despite their structural 
similarities, RIG-I and MDA-5 recognize both common and distinct viral species (Figure 
1.3C). This is likely due to their recognition of overlapping (double-strandedness), but 
distinct (blunt-ends), viral PAMPs: RIG-I is preferentially activated by 5'-triphosphate (5'-
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PPP) containing RNAs and short dsRNAs (Pichlmair et al. 2006; Kato et al. 2008), 
whereas MDA-5 is activated by long dsRNA in which the protein coats the backbone of 
the RNA forming long filamentous structures (Kato et al. 2008; Schlee et al. 2010; 
Peisley et al. 2011; Berke et al. 2012; Ramanan et al. 2012).  
Recent work from our lab has investigated the mechanism by which two different 
filoviruses, Ebolaviruses and Marburgviruses, preferentially antagonize RIG-I and MDA-
5. Despite their similar genome organization and replication strategies, ebolaviruses 
encodes a protein, VP35, that inhibits both RIG-I and MDA-5 recognition of viral RNA. 
However, marburgvirus VP35 only prevents viral RNA recognition by MDA-5 (Ramanan 
et al. 2012). These findings exemplify the distinct, but overlapping, viral recognition of 
RIG-I and MDA-5 and suggest that even closely related viruses generate distinct 
PAMPs which are differentially recognized by these RLRs. Additionally, these studies 
raise the question of what are the true physiological ligands of RIG-I and MDA-5? Such 
a point has been heavily addressed in the literature but has yielded no definitive 
answers. 
 
1.2 Filoviral pathogenesis and epidemiology 
 Viruses, as well as other pathogens, have developed sophisticated means to 
counteract host immune defenses, and filoviruses are capable of an early and potent 
inhibition of host innate immunity. Filoviruses are single-stranded, non-segmented, 
negative sense RNA viruses that cause severe hemorrhagic fever in humans and non-
human primates (Bray et al. 2007), and exhibit fatality rates as high as 90% during 
reported outbreaks. The high lethality associated with filoviral infection is in large part 
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due to an early and potent inhibition of host immune responses. In addition to the 
dysregulation of the host innate and adaptive immune responses, the pathology 
associated with filoviral infection is also, in part, attributed to broad tissue tropism 
allowing the virus to infect and kill a wide variety of cell types and inducing of a strong 
inflammatory response. Though filoviruses can infect a number of different cell types, 
the primary site of infection often occurs in monocytes, macrophages, dendritic cells, 
hepatocytes, and endothelial cells. The induction period for filoviral infection ranges 
between 2 days and 2-3 weeks. The induction period is followed by an onset of non-
specific symptoms including fever, soreness, diarrhea, nausea, and in some cases, a 
maculopapular rash (Bwaka et al. 1999; Feldmann et al. 2011). The disease 
progression of filoviral infection occurs rapidly and after ~2 weeks, the initial non-
specific symptoms can manifest into fatal hemorrhagic fever which is characterized by 
organ failure and severe internal hemorrhaging. Despite the high levels of viral 
replication, potent inhibition of host immune responses, and rapid disease progression, 
there are still no approved vaccines or therapeutic options available to treat filoviral 
infection. The severe pathology exhibited by these viruses and the lack of treatment 
options underscores the potential public health risk posed by filoviruses and the need to 
develop innovative countermeasures. 
 The Filoviridae family consists of two genera, Ebolaviruses and Marburgviruses. 
However, a new genus, Cuevavirus (Negredo et al. 2011; Bukreyev et al. 2013), has 
been proposed. There are two species of Marburgvirus, Marburg virus (MARV) and 
Ravn virus (RAVV) (Kuhn et al. 2010), and five species of Ebolavirus, Ebola virus 
(EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV), Reston virus (RESTV), and 
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Bundibugyo virus (BDBV), all of which are named after the geographical location where 
they were first discovered. The first reported filoviral outbreak occurred in 1967 in 
Marburg, Germany and Yugoslavia when laboratory workers contracted MARV and 
developed a hemorrhagic fever after handling infected tissue samples from monkeys 
imported from Uganda. Since these initial occurrences of marburgvirus, there have 
been other fatal, but sporadic, outbreaks in Kenya and Zimbabwe, and more severe 
outbreaks in the Democratic Republic of Congo and Angola. Within a decade of the first 
reported cases of MARV, ebolavirus emerged with two outbreaks occurring in 1976 in 
the African countries of Zaire and Sudan. Unlike marburgvirus, the initial outbreaks of 
ebolaviruses were not restricted to a small subset of animal handlers, and, in total, 
ebolaviruses has claimed approximately four times the number of lives than 
marburgviruses. The 1976 outbreaks of Ebola virus  and Sudan virus resulted in a 
combined 431 deaths and identified the Zaire strain of ebolavirus as one of the most 
lethal viruses ever isolated, with nearly a 90% fatality rate. At present there are two 
ongoing outbreaks of ebolavirus in Uganda and in the Democratic Republic of Congo 
highlighting the current and ongoing threat these viruses pose to world health.  
 Among the five species of ebolaviruses, RESTV is the only one not of African 
origin and does not cause disease in humans; however, RESTV is highly pathogenic in 
non-human primates (1990; Jahrling et al. 1990; Hayes et al. 1992; Groseth et al. 
2002). Moreover, the recent isolation of RESTV from swine populations in the 
Philippines, suggests the potential zoonotic nature of filoviruses (Jahrling et al. 1990; 
Barrette et al. 2009). In addition to primates and swine, ebolaviral RNA has been 
identified in rodents and shrews from central Africa (Morvan et al. 1999), and bats have 
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been shown to be able to support ebolaviral replication at high viral titers without 
apparent pathological characteristics (Swanepoel et al. 1996). Furthermore, a distinct 
filovirus, Lloviu virus, was recently isolated from insectivorous bats in Cueva del Lloviu, 
Spain (Negredo et al. 2011). These findings have provided insight into the possible 
natural reservoir of filoviruses, with current opinions in the field strongly favoring fruit 
bats, though no definitive conclusion has been agreed upon (Leroy et al. 2005; 
Swanepoel et al. 2007; Pourrut et al. 2009; Towner et al. 2009). Together, these 
observations highlight the zoonotic nature of filoviruses and the importance of 
identifying their elusive natural reservoir, as well as emphasize the need to improve our 
understanding of animal-to-animal transmission in order to better predict and/or contain 
filoviral outbreaks.  
  
1.3 Filoviral viral replication 
 Filoviruses are recognized by their pleomorphic, filamentous morphology and 
have an approximately 19-kilobase genome which encodes seven genes: the viral 
nucleoprotein (NP), viral protein 35 (VP35), VP40, glycoprotein (GP), VP30, VP24, and 
L, the viral RNA-dependent RNA polymerase (Figure 1.4). Filoviurses are enveloped 
viruses with their ribonucleoprotein (RNP)-complex enclosed by a host-derived cell 
membrane. NP, VP35, VP30, and L, along with the viral genomic RNA, comprise the 
RNP-complex. Beneath the viral envelope are viral proteins VP40 and VP24, the major 
and minor matrix proteins, respectively, and embedded in the membrane is the GP 
trimeric spike protein. Viral entry is thought to occur in a GP-dependent manner 
primarily through macropinocytosis, though alternative mechanism such as caveolin-
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dependent and clathrin-dependent endocytosis have been proposed (Nanbo et al. 2010; 
Saeed et al. 2010; Aleksandrowicz et al. 2011; Hunt et al. 2011). Given the broad tissue 
tropism exhibited by filoviruses, the cellular receptors involved in filoviral entry are 
poorly understood.  
 Once in the cytoplasm, ebolavirus, like all negative-stranded RNA viruses, must 
carry out de novo synthesis of viral mRNA (Knipe 2001). Due to the fact that ebolavirus 
replicates through RNA intermediates, the virus must encode its own RNA-dependent 
RNA polymerase and package the polymerase into the virion in order to carry out 
transcription once inside newly infected cells. The ebolavirus RNA-dependent RNA 
polymerase complex is responsible for both viral transcription and replication, and 
consists of four viral proteins: NP, VP35, VP30, and the polymerase, L (Figure 1.5). 
The molecular basis for protein-protein and protein-RNA interactions that establish the 
polymerase complex, as well as the molecular switch between replication and 
transcription are currently unknown. Initial studies with marburgvirus, and subsequent 
studies with ebolavirus, established that NP, VP35, and L are the minimal components 
required for viral replication (Becker et al. 1998; Muhlberger et al. 1998; Muhlberger et 
al. 1999). Though VP30 is not required for replication, it has been shown to be 
important for transcription initiation within the context of ebolaviral infection, but not 
marburgviral infection (Muhlberger et al. 1998; Muhlberger et al. 1999; Weik et al. 
2002). Following viral entry, the viral polymerase complex transcribes polyadenylated, 
monocistronic viral mRNAs which contain a 5'-cap allowing for cap-dependent 
translation of the viral mRNA (Shabman et al. 2013). The filoviral genome is arranged in 
a 3'-5' orientation, with the general abundance of each viral proteins correlating to the 
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proximity of its gene to the 3' end. This is due to a gradual decrease in the levels of 
mRNA of the NP gene at the 3' end relative to the viral polymerase gene, L, at the 5' 
end (Knipe 2001). It is tempting to speculate that the decrease in mRNA levels moving 
from the 3' to 5' direction of the genome results from the polymerase complex 
dissociating from the genomic viral RNA template, but the mechanism(s) by which 
filoviruses carry out viral transcription and regulate the levels of their transcripts are 
currently not understood.  
The viral mRNA generated during viral transcriptions is then translated by host 
cell machinery to produce viral proteins. An accumulation of viral proteins, particularly 
NP, within the cell triggers the RNA-dependent polymerase complex to switch from 
transcription to replication. In the context of viral replication, the viral polymerase 
complex first generates a positive sense anti-genome, which like the negative sense 
genome, is encapsidated by NP. The resulting anti-genome intermediate then serves as 
the template for synthesis of the negative sense genome. The newly synthesized viral 
genome can then serve as a template for the transcription of additional viral mRNA 
and/or be packaged into a budding virion. Little is known about how the polymerase 
complex switches between transcription and replication, but the phosphorylation state of 
VP30 plays a critical role in determining whether the polymerase complex supports 
replication or transcription (Biedenkopf et al. 2013). Additionally, a recently published 
study has identified regulatory roles for VP40 and VP24 in viral transcription (Hoenen et 
al. 2010), suggesting that the dynamics between viral replication and transcription are 
tightly regulated.  
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 Viral assembly, budding, and egress are mediated through the viral matrix 
proteins, VP40 and VP24. VP40 is the more abundant of the two proteins and alone is 
sufficient for the formation of virus-like particles (VLP) that resemble authentic virions 
(Harty et al. 2000; Yasuda et al. 2003). Though VP40 can mediate the budding process 
independently, in the context of an infection it supports a number of critical interactions 
with viral and host components to properly coordinate assembly and budding. Once the 
virion egresses from the infected host cell, it can infect a new cell where the replication 
cycle can be carried out again. 
 
1.4 Filoviruses encode multiple virulence factors 
 Of the seven proteins encoded by ebolavirus, VP24, GP, and VP35 are known 
virulence factors. These three proteins function to subvert and inhibit host immune 
defenses permitting the virus to antagonize both innate and adaptive immune 
responses (Figure 1.6). Attesting to the potent ability of these proteins to counter host 
immunity, fatal cases of filoviral infection often indicate no activation of adaptive 
immunity though these individuals were immunocompetent.  
 Filovirus infection potently inhibits the innate immune system by stunting host 
secretion of IFN-β. However, in instances where IFN-β is produced, the EBOV minor 
matrix protein VP24 is able to antagonize downstream IFN-β signaling molecules 
(Figure 1.6). IFN-β can act in an autocrine or paracrine fashion to activate the 
JAK/STAT pathway, a pathway which allows for the phosphorylation and translocation 
of STAT transcription factors into the nucleus where they stimulate the production of a 
number of anti-viral ISGs. Ebolaviral VP24 inhibits this pathway by interacting with 
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karyopherin-α (KPNA), a protein involved in the importin complex which helps shuttle 
STAT into the nucleus (Reid et al. 2006; Mateo et al. 2010; Shabman et al. 2011; Zhang 
et al. 2012). One important aspect of VP24-mediated inhibition is the potential to disrupt 
KPNA-dependent translocation of many other transcription factors to the nucleus, thus 
drastically changing the expression profile within an infected cell.  
 The fourth gene encoded by ebolavirus is the viral glycoprotein, GP, which plays 
a role in antagonizing the adaptive immune response. GP is the only viral protein 
located on the surface of the virion, and therefore the immunodominant antigen targeted 
by host antibodies. The GP gene encodes for two proteins as a result of transcriptional 
editing (Feldmann et al. 1999). A secreted form of GP, soluble GP (sGP), represents 
the unedited form of the gene and accounts for approximately 80% of the transcribed 
mRNA (Feldmann et al. 2001). Given the unbalanced ratio of sGP to membrane bound 
GP, it is believed that the high levels of circulating sGP can act as a decoy by serving 
as a “sink” for neutralizing antibodies, preventing them from binding to cell-surface GP 
(Mohamadzadeh et al. 2007).  
 Ebolaviral VP35 is a multifunctional immune antagonist that functions at several 
stages in the viral replication cycle (Basler et al. 2000; Basler et al. 2003; Cardenas et 
al. 2006; Hartman et al. 2006; Leung et al. 2010). VP35 is known to antagonize 
numerous components in the IFN induction and signaling pathway (Basler et al. 2000; 
Basler et al. 2003; Hartman et al. 2004; Cardenas et al. 2006; Enterlein et al. 2006; 
Hartman et al. 2006; Feng et al. 2007; Haasnoot et al. 2007; Hartman et al. 2008; 
Leung et al. 2010), including RLRs (Cardenas et al. 2006; Prins et al. 2010; Luthra et al. 
2013), IFN kinases IKKε and TBK-1(Prins et al. 2009), RNA-dependent protein kinase 
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(PKR) (Feng et al. 2007; Schumann et al. 2009), and PKR activator (PACT) (Luthra et 
al. 2013). VP35 also functions as an RNAi silencing suppressor (Haasnoot et al. 2007; 
Fabozzi et al. 2011), a co-factor for the viral polymerase (Becker et al. 1998; 
Muhlberger et al. 1998; Muhlberger et al. 1999; Prins et al. 2010), and a structural 
component of the viral nucleocapsid (Huang et al. 2002; Noda et al. 2002; Johnson et 
al. 2006; Shi et al. 2008).  
In an effort to better understand VP35 and VP35 mediated functions, our lab has 
taken both a structural and functional approach to define the critical intermolecular 
interaction involving VP35. These efforts resulted in the crystal structure of the C-
terminal domain of VP35, termed the interferon inhibitory domain (IID) (Leung et al. 
2009; Leung et al. 2010). The VP35 structure revealed two basic patches, termed the 
first basic patch (FBP) and the central basic patch (CBP), which are highly conserved 
among ebolaviral species (Figure 2.1). Using the structural data in conjunction with 
previously published biochemical data (Hartman et al. 2004), residues known to be 
important for interferon inhibition were mapped to the CBP of VP35 IID. More recently, 
our lab has determined the crystal structure of the VP35 IID bound to dsRNA (Leung et 
al. 2010), and in doing so, clarified the mechanism by which the VP35 CBP interacts 
with dsRNA and inhibits host immune responses. In the crystal structure four VP35 IID 
molecules interact with 8 base pair (bp) dsRNA through direct contacts with the 
phosphodiester backbone and blunt ends (Figure 1.7A). Residues R312, K319, R322, 
and K339 are critical CBP residues responsible for interacting with the RNA backbone, 
whereas hydrophobic residue F239 is responsible for 'end-capping' the blunt ends. 
Alanine substitution mutations to either the CBP residues or the ‘end-capping’ residues 
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disrupt the VP35 IID-dsRNA interaction and correspondingly inhibit the induction of IFN-
β.  
The strong correlation between dsRNA binding and inhibition of IFN-β production 
suggests a mechanism by which VP35 sequesters dsRNA and prevents detection by 
RLRs. Work from our lab has established that VP35 can out-compete RIG-I for dsRNA 
binding, further supporting a model in which VP35 antagonizes host immune responses, 
at least in part, by preventing activation of RLRs. Moreover, recent structural studies 
revealed an interaction between RIG-I and the blunt ends of dsRNA, indicating that 
double-strandedness and the blunt ends are common ligands recognized by both RIG-I 
and VP35 (Figure 1.7B and C) (Leung et al. 2010; Ramanan et al. 2012). Further 
supporting the critical role of the VP35 CBP in viral pathogenesis, a guinea pig adapted 
ebolavirus was engineered with alanine mutations to CBP residues K319 and R322. 
The CBP mutant virus was severely attenuated despite being replication competent. 
Prior infection with the mutant virus conferred protection against subsequent infection 
by wild-type (WT) ebolavirus, suggesting that if the guinea pig can mount an effective 
adaptive immune response these animals are immunized against ebolavirus (Prins et al. 
2010). In addition to the dsRNA-dependent mechanism of inhibition of IFN-β production, 
VP35 is also able to inhibit in an RNA-independent manner. While the exact mechanism 
by which this occurs is not clear, VP35 appears to serve as a pseudosubstrate for IKKε 
and TBK-1, two kinases which phosphorylate IRF-3/7 (Prins et al. 2009). Direct 
inhibition of these kinases would provide a possible explanation for RNA-independent 
inhibition of IFN-β production downstream of RLRs. Altogether, these studies highlight 
the importance of VP35 proteins in viral-mediated host immune suppression and 
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support a model in which VP35 binds dsRNA preventing its recognition by RLRs. 
Additionally, this work establishes a framework for targeting VP35 with potential 
therapeutics. 
 
1.5 VP35 as a therapeutic target 
 Despite a substantial body of literature describing the molecular mechanisms that 
drive filoviral pathogenesis, there are still no FDA-approved treatments for filoviral 
infections (Wilson et al. 2001; Geisbert et al. 2003; Hensley et al. 2005; Bray et al. 
2007; Geisbert et al. 2010; Hartman et al. 2010; Feldmann et al. 2011). Though filoviral 
outbreaks are sporadic, and thus far restricted to rural regions of Africa, the high fatality 
rates, zoonotic nature, and threat of exploitation by bioterrorists underscore the public 
health threat these viruses pose. 
 The relevance of VP35 to host immune inhibition and viral replication make it an 
attractive target for therapeutic development. Previous studies have demonstrated that 
antisense oligonucleotides and small interfering RNAs can interfere with EBOV 
replication by targeting VP35 (Enterlein et al. 2006; Geisbert et al. 2006; Warfield et al. 
2006; Groseth et al. 2007). Additional studies indicate that ebolaviruses containing 
mutant VP35 are highly attenuated and guinea pigs infected with these mutant 
ebolaviruses are protected against challenges with wildtype ebolavirus (Prins et al. 
2010). 
 My thesis will focus on deconstructing the many roles of the multifunctional VP35 
protein, assessing the potential of VP35 as a therapeutic target, and developing VP35 
inhibitors. Specifically, I have investigated the role of the VP35 C-terminal domain 
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termed the interferon inhibitory domain (IID) in viral replication through its interaction 
with NP. In an effort to target the two functionally relevant basic patches of VP35 with 
inhibitory molecules, we have identified and characterized anti-VP35 RNA aptamers 
selected against Ebola virus (EBOV) VP35 (eVP35) IID WT and mutant proteins. 
Through these studies we have determined that the aptamers bind with high affinity and 
specificity to eVP35 IID and disrupt the eVP35-NP interaction. Correspondingly, 
aptamers that disrupt the eVP35-NP interaction inhibit the functionality of the viral 
polymerase complex in a reconstituted minigenome (MG) assay. As viral replication is a 
critical step in viral propagation, an enhanced understanding of this process at the 
molecular level will undoubtedly aid in the development of therapeutics. My thesis 
provides much needed biochemical insight into the formation of the ebolaviral RNA-
dependent RNA polymerase complex by analyzing the critical residues within eVP35 IID 
at the VP35-NP interface, further implicating VP35 as a promising target for antivirals. 
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1.6 Figures 
 
Figure 1.1. Pattern recognition receptors allow for early detection of invading 
pathogens. (A) Pathogen associated molecular patterns (PAMPs) are dectected by 
cellular proteins termed pattern recongition receptors (PRRs). Once the PRRs detect a 
PAMP, in this case a viral PAMP, the PRR elicits an innate immune response to counter 
and clear the invading pathogen. (B) Four classes of PRR, C-type lectin receptors 
(CLRs), Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I like receptors 
(RLRs), detect pathogens at the cell surface, in the endosomal compartment, and within 
the cytoplasm. 
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Figure 1.2. Type I IFN pathway can be divided into the IFN production and IFN 
response pathways. Cytosolic RLRs detect viral PAMPS, including dsRNA, and trigger 
a signal transduction cascade which results in the phosphorylation and translocation of 
IRF-3/7 to the nucleus where it stimulated the production of IFN-β. IFN-β can act in an 
autocrine or paracrine fashion to activate the JAK/STAT pathway and upregulate IFN-
stimulated genes (ISGs) ultimately establishing an anti-viral state within the cell. 
Adapted from (Leung et al. 2010). 
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Figure 1.3. RIG-I like receptors detect RNA viruses. (A) RLRs include RIG-I, MDA-5, 
and LGP2. Both RIG-I and MDA-5 both contain two tandem CARD domains at their N-
termini, this is followed by a helicase domain followed by a C-terminal domain (CTD). 
LGP2 contains the helicase and CTD similar to RIG-I and MDA-5 but is lacking the N-
terminal CARD domains. (B) RIG-I and MDA-5 can recognize viral dsRNA and activate 
the Type-I IFN signalling pathway through the mitochondrial anchored adapter protein 
and  (B) (C) Viral activators of RIG-I (top, white box), both RIG-I and MDA-5 (middle, 
light grey box), and MDA-5 (bottom, dark grey box) (adapted from Loo et al. (Loo et al. 
2008)). 
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Figure 1.4. The basic architecture of the filoviral virion. (A) Electron micrograph of 
the ebolavirus virion displays the characteristic filamentous appearance from which 
filoviruses derive their name. (Centers for Disease Control and Prevention; 
http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Ebola_Fact_Bookl
et.pdf). (B) Filoviruses are enveloped, single-stranded, non-segmented, negative sense 
RNA viruses (-ssRNA). The viral envelope is embedded with the viral glycoprotein, GP,  
and beneath the membrane is the viral major and minor matrix proteins, VP40 and 
VP24, respectively. Within the virion is the ribonucleoprotein (RNP) complex which is 
made up of NP, VP35, VP30, and L which is associated with the viral genomic RNA. (C) 
The viral genome is oriented in the 3'-5' orientation and encodes seven genes.  
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Figure 1.5. Ebolavirus replication complex is responsible for both viral 
transcription and replication. (A) The minimal ebolavirus RNA-dependent RNA 
polymerase complex is comprised of viral proteins NP, VP35, and L, with the addition of 
VP30 being required for viral transcription (Becker et al. 1998; Muhlberger et al. 1998). 
(B) The ebolavirus polymerase compex is required for both viral transcription and 
replication. (1) Upon viral entry, the nucleocapsid is released into the cytoplasm. (2) The 
ebolavirus polymerase complex then transcribes viral mRNA. Translation of viral mRNA 
by host cell machinery results in an abundance of viral protein within the cell, triggering 
the ebolavirus polymerase complex to switch from transcription replication. (4) The 
negative sense genomic viral RNA is synthesized through a positive sense RNA 
intermediate and (5,6) subsequently packaged into a budding virion. Adapted from 
Fields Virology (Knipe 2001). 
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Figure 1.6. Ebolaviruses antagonize multiple host immune pathways. Ebolaviral 
encoded VP35, VP24, and GP antagomize host immune responses. VP35 inhibits the 
production of IFN-β by binding to and sequestering dsRNA, thus preventing its detection 
by RLRs (left). VP24 inhibits the IFN-β response pathway by engaging KPNA and 
preventing the translocation of STAT to the nucleus (middle). The mechanism(s) of GP 
inhibition are less well defined, but the most prevalant models suggest sGP and 
'dispatched' GP can bind to antibodies and prevent their association with cell-surface 
GPs (right). 
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Figure 1.7. eVP35 IID binds to dsRNA and compared with RIG-I for dsRNA 
binding. (A) The crystal structure of eVP35 IID bound to 8-base pair dsRNA (PDB ID: 
3L25) reveals that four VP35 IID molecules associate with both the blunt ends of the 
dsRNA (VP35 IIDs shown in blue) and the phosphodiester backbone (VP35 IIDs shown 
in teal). The dsRNA is shown in pink. (B) 90˚ rotation of (A) showing only two VP35 
molecules highlights the ability of VP35 to bind the blunt- ends and backbone of dsRNA. 
(C) Pymol alignment of VP35 IID and RIG-I dsRNA bound strucutres, with the RNA 
molecules aligned. Based on the alignment, VP35 and RIG-I sterically clash, suggesting 
that in vivo VP35 and RIG-I compete for the same ligand. C-terminal domain of RIG-I 
bound dsRNA (PDB ID: 3OG8) (Lu et al. 2011). 
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CHAPTER 2. FUNCTIONAL VALIDATION OF THE VP35 IID FIRST BASIC PATCH 
 
The research within this chapter consists of data that are published in the Journal of 
Virology. 
 
Prins, K.C., Binning, J.M., Shabman, R.S., Leung, D.W., Amarasinghe, G.K., and 
Basler, C.F. (2010) Basic residues within the ebolavirus VP35 protein that are required 
for its viral polymerase cofactor function. J. Virol. 84:10581–10589. 
 
This work was a collaboration between the Basler and Amarasinghe laboratories. My 
contributions to this manuscript included the expression and purification of VP35 IID WT 
and mutant proteins for the NMR and ITC experiments, carrying out the NMR and ITC 
experiments, as well as purifying all of the MBP-fusion VP35 IID proteins used in the NP 
pulldown assays. Additionally, I cloned the lysine-to-arginine and arginine-to-lysine 
mutations to address reviewer’s comments during the submission process. In addition 
to data analysis, I drafted and edited then methods, results and discussion sections 
pertaining to my work.  
 
2.1 Introduction 
 Filoviral VP35 is a well known immune antagonist as described in Chapter 1. In 
addition to being vital for immune suppression, VP35 is a critical component of the viral 
polymerase complex. The multifunctional nature of VP35 provides opportunities to 
investigate host immune suppression mechanisms, negative-stranded viral RNA 
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synthesis, and the basis for one protein to mediate multiple functions and support 
multiple binding partners. EBOV VP35 engages in a number of intermolecular 
interactions with viral proteins such as nucleoprotein (NP) (Becker et al. 1998), the large 
protein (L) (Moller et al. 2005), and VP40 (Johnson et al. 2006), and cellular 
components such as dsRNA (Cardenas et al. 2006; Haasnoot et al. 2007; Leung et al. 
2010; Leung et al. 2010), IKKε (Prins et al. 2009), TBK-1 (Prins et al. 2009), IRF-7 
(Chang et al. 2009), and PKR (Feng et al. 2007; Schumann et al. 2009). VP35 is 
composed of an N-terminal oligomerization domain and a C-terminal interferon 
inhibitory domain (IID). To better understand VP35 and VP35 mediated functions, our 
lab has taken both a structural and functional approach which has resulted in a crystal 
structures of VP35 IID alone and bound to dsRNA revealing two highly conserved basic 
patches, the FBP and the CBP. Biochemical data implicated a number of basic residues 
within IID as important for dsRNA binding (Hartman et al. 2004; Leung et al. 2010), but 
the availability of the VP35 IID-dsRNA structure provided important insight in to how 
these residues formed a basic patch, the CBP, and how this basic patch binds to viral 
dsRNA and prevents its detection by RLRs. In contrast to the CBP, the FBP was not 
required for inhibiting the production of IFN-β. Some, but not all VP35 mediated 
functions depend on the ability of VP35 to bind dsRNA. In addition to its role in host 
immune inhibition, VP35 is an essential component of the filoviral replication complex. 
Co-expression and immunofluorescence studies by Becker et al. revealed cellular 
localization patterns for filoviral proteins. In the context of viral infection, NP, VP30 and 
VP35 all co-localized within inclusion bodies. When expressed individually, NP was 
found to localize within inclusion bodies, while VP30 and VP35 were distributed 
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throughout the cell. When VP30 or VP35 were co-expressed with NP they went from 
being homogenously dispersed to being found in NP-induced inclusion bodies. These 
studies established interactions between NP-VP35, NP-VP30, VP35-L, and NP-VP35-L, 
and support a model in which VP35 interacts with both NP and L, thus tethering the 
polymerase and its template together. Here we biochemically characterize the eVP35 
FBP residues and demonstrate that the FPB is not involved in dsRNA binding, but is 
critical for the polymerase cofactor function of VP35 (Prins et al. 2010). Although the 
exact role of these VP35 residues in replication is poorly defined, we show that the 
replication defective FBP mutations loss their ability to interact with NP, but maintain the 
VP35-L interaction. Together these results further our understanding of the protein-
protein interactions that establish the EBOV polymerase complex and our data supports 
a model where two distinct regions of VP35 contribute to pathogenesis through 
polymerase co-factor function and IFN inhibition/dsRNA binding. 
.  
2.2 Materials and methods 
Antibodies. Monoclonal antibodies against Zaire EBOV VP35 and against Zaire EBOV 
NP were generated in collaboration with the Mount Sinai Hybridoma Center and have 
been described previously (Cardenas et al. 2006; Martinez et al. 2007). A monoclonal 
antihemagglutinin (anti-HA) antibody was purchased from Sigma (St. Louis, MO). A 
monoclonal anti-maltose binding protein (anti-MBP) antibody was purchased from New 
England Biolabs. 
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Cell lines and viruses. HEK293T cells and Vero cells were maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum (FBS) at 37°C and 
5% CO2. Sendai virus (SeV) strain Cantell was grown in 10-day-old embryonated 
chicken eggs for 2 days at 37°C. 
 
Plasmids. The Zaire EBOV VP35 expression plasmid pCAGGS-VP35 and an IFN-
promoter reporter plasmid were described previously (Basler et al. 2000; Basler et al. 
2003). VP35 point mutations were generated by standard PCR-based methods and 
cloned into the mammalian expression plasmid pCAGGS (Niwa et al. 1991). Firefly 
luciferase was expressed from the pCAGGS plasmid in the minigenome assays (see 
below). The pRL-TK Renilla luciferase expression plasmid was purchased from 
Promega (Madison, WI). Sequences encoding Zaire EBOV L amino acids 1 to 505 (HA-
L amino acids 1 to 505) were amplified from plasmid pTM1-L by PCR (Prins et al. 
2010), cloned with an amino-terminal HA tag, and cloned into pCAGGS. The expression 
plasmid for Zaire EBOV NP, pcDNA3 EBOV NP, has been described previously 
(Martinez et al. 2007). 
 
MBP-fusion VP35 IID and VP35 IID protein expression and purification. MBP-fusion 
VP35 IID proteins were expressed and purified as described previously (Leung et al. 
2009; Leung et al. 2009). Briefly, BL21(DE3) cells expressing MBP-fusion VP35 IID 
proteins were lysed using an EmulsiFlex-C5 homogenizer (Avestin) and clarified by 
centrifugation at 30,000 g at 4°C for 30 min. The supernatant was purified by affinity and 
cation-exchange chromatography, prior to final purification by size exclusion 
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chromatography. For VP35 IID proteins, the fusion tags were removed prior to final 
purification by cleavage with tobacco etch virus (TEV) protease followed by size-
exclusion chromatography. The purity of the protein samples was assessed by SDS-
PAGE. 
 
Nuclear Magnetic Resonance (NMR). 300μl samples were prepared at 100μM 15N 
labeled VP35 IID in 10mM HEPES (pH 7), 150mM NaCl, 2mM Tris(2-
carboxyethyl)phosphine (TCEP)  and 5% D2O buffer. 
1H15N heteronuclear single 
quantum coherence (HSQC) experiments were collected at 25°C on a Bruker Avance II 
spectrometer [700.13MHz]. Data were processed with NMRPipe/NMRDraw and 
analyzed in NMRView. 
 
Isothermal titration calorimetry (ITC) assays. Quantitative analysis of VP35 IID 
protein binding interactions with dsRNA was performed on a microcalorimeter (VP-ITC; 
Microcal, North Hampton, MA) by isothermal titration calorimetry (ITC), using protein 
samples dialyzed against 500 ml of dialysis buffer [10 mM HEPES (pH 7.0), 150 mM 
NaCl, 1 mM MgCl2, 2 mM TCEP)] for 12 h. The resulting raw microcalorimeter data 
were processed and analyzed to determine n (number of binding sites) and KD (binding 
constant) using ORIGIN software. Protein concentrations in the syringe were between 
130 to 150 µM and dsRNA 8mer in the cell was at 4 to 6 µM, using 5 cal/sec as the 
reference power. 
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IFN-β–luciferase reporter assay. HEK293T cells were transfected by using 
Lipofectamine 2000 (Invitrogen) with the indicated amounts of expression plasmid, an 
IFN-β–firefly luciferase reporter plasmid (400 ng), and a constitutively expressed Renilla 
luciferase reporter plasmid (pRLTK, 200 ng). To induce reporter gene expression, cells 
were infected with SeV at a multiplicity of infection of 10. Twenty-four hours 
posttransfection, the cell lysates were assayed with the dual luciferase reporter assay 
(Promega), and firefly luciferase activity was normalized to Renilla luciferase activity. 
The results are presented as percent induction of the positive control (SeV infected, 
empty vector transfected [no VP35]), the value for which was set equal to 100%.  
 
EBOV transcription/replication assay. The EBOV transcription/replication assay was 
based on a previously described system (Muhlberger et al. 1999). HEK293T cells were 
cotransfected by the calcium phosphate precipitation method with phage T7-driven 
expression plasmids encoding the Zaire EBOV NP, L, and VP30 and VP35 proteins. 
Also transfected were a T7 RNA polymerase expression plasmid, a plasmid that 
expresses from a T7 promoter a Zaire EBOV minigenome which encodes a fused green 
fluorescent protein (GFP)-chloramphenicol acetyltransferase (CAT) reporter gene. This 
is flanked by the cis-acting sequences necessary for replication and transcription of the 
RNA by a reconstituted EBOV polymerase complex. Also transfected was a 
constitutively expressing luciferase expression plasmid that served as a transfection 
control. At 36 h posttransfection, cells were lysed with reporter lysis buffer (Promega) 
and both CAT and luciferase reporter activities were determined. CAT activity was 
normalized to luciferase activity. Minigenome reporter activation is presented as percent 
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activity relative to that of the positive-control reaction (250 ng of wild-type (Emsley et al.) 
VP35 plasmid), which was set equal to 100%. Error bars represent the standard 
deviation (SD) from at least three experiments. 
 
Immunoprecipitations (IPs). To immunoprecipitate full-length VP35 proteins, lysates 
from transfected cells were incubated with 1 µg of anti-VP35 monoclonal antibody 
overnight at 4°C, followed by 1 h incubation with protein G-Sepharose beads (Roche). 
The beads were washed five times with lysis buffer. After the beads were washed, they 
were resuspended in SDS-PAGE sample loading buffer, separated by 10% SDS-PAGE, 
and analyzed by Western blotting, as indicated. 
 
MBP-VP35 IID fusion protein interactions with NP. Forty-five micrograms of pcDNA3 
EBOV NP was transfected into 3 x 107 HEK293T cells. At 24 h posttransfection, the 
cells were lysed in 4 ml NP-40 lysis buffer (50 mM Tris-HCl [pH 8], 280 mM NaCl, 0.5% 
NP-40, 0.2 mM EDTA, 2 mM EGTA, and 10% glycerol with protease inhibitors). 350µl of 
clarified lysate was incubated with the VP35 IID domain fused with MBP or equivalent 
amounts of the MBP-mutant IID fusion proteins at 4°C. Twenty-four hours later, MBP 
fusion proteins were bound with 40 ml of amylose resin for 30 min. The resin was 
washed three times, and MBP fusion proteins were eluted with 100 ml of 10 mM 
maltose. A fraction of the elution was analyzed by Western blotting. MBP was detected 
with an anti-MBP antibody (New England Biolabs), and NP was detected with the 
previously described (see above) anti-NP mouse monoclonal antibody. To determine if 
the MBP-VP35 IID fusion proteins could interact with NP in the presence of dsRNA, 
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lysates expressing NP were generated as described above. Before addition of the MBP-
VP35 IID protein to the cellular lysate, increasing amounts of poly(I:C) (Invitrogen) were 
first added to the lysate. Poly(I:C) was added at a concentration of either 16 or 98 nM, 
while either WT or mutant VP35 IID was used at a concentration of 2.4  µM. Following a 
24-h incubation period, samples were processed as described above. 
  
2.3 Results 
 2.3.1 FBP is not important for dsRNA binding or immune inhibition 
 The structure of eVP35 IID was solved to 1.4 Å and revealed a novel RNA 
binding fold comprised of an alpha helical and beta sheet sub-domain (Leung et al. 
2009). Residues K222, R225, K248, and K251 form the FBP, which is located on the 
alpha helical sub-domain, and residues R312, K319, and R322 are three primary 
residues that form the CBP, which is located on the beta sheet sub-domain (Figure 
2.1). The CBP residues had previously been shown to be important for dsRNA binding 
and host immune inhibition (Leung et al. 2010), but it was not clear what role, if any, the 
FBP played in VP35 mediated functions. In order to assess the functional relevance of 
the FBP and determine whether FBP mutations (R225A, K248A, and K251A) affected 
the structural integrity of eVP35 IID or its ability to bind dsRNA, we carried out NMR and 
ITC studies. 1H/15N HSQC spectra were collected for each FBP mutant and compared 
to the corresponding eVP35 IID WT spectra. Figure 2.2 displays the 2-D HSQC spectra 
for the FBP mutants alone and overlaid with eVP35 IID WT. Each chemical shift in a 
1H/15N HSQC spectra arises from a non-proline amide group and is sensitive to its 
immediate surroundings or local environment. As expected, the alanine substitutions 
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gave rise to small chemical shift perturbations due to the changes in local environment 
at the site of mutation, but overall no global changes to the protein fold were observed. 
Consistent with these structural studies, our ITC data shows that the FBP mutants 
retain their ability to bind dsRNA. Alanine substitution mutants R225A, K248A, and 
K251A bound 8 base pair (bp) dsRNA comparable to wild-type eVP35 IID with KD 
values of 0.7 µM, 1.0 µM, 2.4 µM, 0.8 µM, for eVP35 IID WT, R225A, K248A, and 
K251A, respectively (Figure 2.3). Together, these data clearly show that mutations to 
FBP residues cause minimal perturbations to the overall structure of eVP35 IID and 
have no effect on dsRNA binding.  
 
 
2.3.2 FBP residues are involved in EBOV replication  
 In addition to its role in host innate immune suppression, VP35 is a critical 
component of the filoviral polymerase complex. In contrast to the CBP, the FBP was 
shown to be not important for binding dsRNA or inhibiting the production of IFN-β. In 
order to determine the role, if any, of the FBP in viral replication, we employed an EBOV 
minigenome assay (Figure 2.4). In this assay, an EBOV minigenome is constructed by 
flanking a reporter gene (GFP-CAT or luciferase) with the 3' and 5' EBOV leader and 
trailer sequences which contain the necessary cis-acting elements required by the 
EBOV replication complex. The viral polymerase complex is reconstituted by the 
expression of viral proteins NP, VP35, VP30, and L, and if these proteins come together 
to form a functional polymerase complex, then the minigonome can serve as the 
template for RNA synthesis ultimately resulting in the expression of the reported gene 
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(Muhlberger et al. 1998; Muhlberger et al. 1999). As has previously been shown, the 
presence of VP35 was required for minigenome activity. FBP mutants R225A, K248A, 
and K251A completely abolished minigenome activity, whereas the mutant K222A 
retained its polymerase co-factor function similar to WT (Figure 2.5). These results 
indicate that three out of the four FBP residues, R225, K248, and K251, are important 
for the VP35 polymerase cofactor function.  
 In addition to the alanine substitution mutants, we also generated glutamic acid 
substitution mutants and lysine-to-arginine or arginine-to-lysine mutants. All of the 
eVP35 IID glutamic acid substitution mutants expressed to comparable levels, and 
similar to the alanine substitution mutants, lost their ability to support minigenome 
activity (Figure 2.6A). In contrast to the alanine and glutamic acid substitution mutants, 
lysine-to-arginine or arginine-to-lysine mutations, in which lysine residues were mutated 
to arginine and vice versa, showed that the FBP basic residues are interchangeable as 
these mutation have little to no effect on minigenome activity (Figure 2.6B). Therefore, 
the basic charge of the FBP residues, and not the identity of the residues, is the 
important factor in determining eVP35 IID functionality in the minigenome assay.  
 
2.3.3 FBP residues are involved in NP interaction 
 Previous work by Becker et al. has established an interaction between NP and 
VP35 as indicated by the co-localization of both proteins into NP induced inclusion 
bodies (Becker et al. 1998). To determine whether the inability of the VP35 FBP 
mutants to function in the minigenome assay could be explained by the loss of 
interaction with NP, we employed a combination of co-immunoprecipitation (Co-IP) and 
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pulldown assays. For the co-immunoprecipitation assays, NP was co-transfected into 
HEK293T cells in the absence or presence of WT or mutant eVP35s. FBP mutants 
R225A and K248A displayed no detectable interaction with NP, whereas mutant K251A 
displays a significantly diminished ability to interact with NP  (Figure 2.7A). However, 
mutants R225A and K248A expressed at a lower level compared to WT and displayed 
an unusual migration pattern, running unexpectedly high on the SDS-PAGE gel. In 
addition to the FBP mutants, CBP residues, 'end-capping' residues, and conserved 
basic residues bordering the CBP (border basic residues) were assessed for their ability 
to interact with NP. With the exception of H240A, all of these additional mutants 
maintained the ability to bind NP. Similar to R225A and K248A, H240A displayed an 
unusual migration pattern on the SDS-PAGE gel. Follow up experiments investigating 
the H240A mutation in the context of eVP35 IID revealed stability issues, possibly 
explaining its inability to bind NP in the present assay. Consistent with the Co-IP results, 
a MBP pulldown assay showed that MBP fused eVP35 IID (MBP-eVP35 IID) protein 
was able to interact with NP whereas MBP alone cannot, indicating that the IID alone is 
sufficient to interact with NP (Figure 2.7B). Moreover, the MBP-eVP35 IID R225A and 
K248A mutants were expressed to comparable levels relative to WT yet still displayed 
no detectable interaction with NP, therefore allowing us to more accurately conclude 
that the loss of minigenome activity exhibited by eVP35 mutants R225A, K248A, and 
K251A is due to loss of critical contacts with NP.  
 VP35 establishes multiple interactions in the context of both host immune 
evasion and viral replication. It is unknown whether VP35 can carry out both functions 
simultaneously or if it partitions between the two functions. In order to address this 
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question, we tested the ability of VP35 IID to bind NP the absence or presence of 
dsRNA (Figure 2.7C). To this end, MBP-eVP35 IID was bound to NP, and incubated 
with increasing amounts of poly I:C. MBP-eVP35 IID WT displayed a diminished ability 
to bind NP in the presence of poly I:C, but dsRNA binding mutants F239A, R312A, and  
R322A were unaffected. These results suggest that the dsRNA binding function of VP35 
can influence the VP35-NP interaction in a way where both of these binding interactions 
may not be able to occur concurrently. More work is needed to understand 
mechanistically how VP35 carries out its multiple function. Specifically the use of RNA 
ligands which better mimic the physiological dsRNA recognized by VP35 would benefit 
these studies as it has been shown that small dsRNA (18mers) cannot replicate the 
results presented here for poly I:C (data shown in Figure 4.16).  
 
2.3.4 VP35 FBP and CBP residues are not important for VP35-L interaction 
 Initial studies with MARV, and subsequent studies with EBOV, have established 
that NP, VP35, and L are the minimal components required for viral replication 
(Muhlberger et al. 1998). These studies have clearly demonstrated interactions between 
NP-VP35, NP-VP30, VP35-L, and NP-VP35-L, supporting a model in which VP35 
interacts with both NP and L, thus tethering the polymerase and its template together. 
Due in part to its large size, studies with the viral polymerase have been limited. 
However, it was been shown for MARV L that the N-terminal 1-503 residues are 
sufficient to interact with MARV VP35. Translating these findings from MARV to EBOV, 
we were able to show that the first 1-505 residues from EBOV L are sufficient to interact 
with eVP35. Using our panel of eVP35 mutants we assessed the importance of these 
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residues in the VP35-L interaction. All the tested mutants maintained the ability to 
interact with L (Figure 2.8) indicating that FBP residues, CBP residues, border basic 
residues, and 'end-capping' residues are not important for the VP35-L interaction. 
Furthermore, it has been shown that homo-oligomerization of MARV VP35 through its 
N-terminus is required for the MARV VP35-L interaction, hence the use of full-length 
eVP35 in the present studies (Moller et al. 2005). These data together with the pulldown 
results strongly suggest that the VP35-L interaction may be mediated through the N-
terminus of VP35 with little to no contribution from the C-terminus.  
 
2.4 Conclusions 
 The molecular basis for protein-protein and protein-RNA interactions that 
establish the polymerase complex, as well as the molecular switch between replication 
and transcription are currently unknown. Work described here begins to shed light on 
the critical VP35-NP interaction, and identifies the importance of the VP35 FBP residues 
in viral replication. The EBOV RNA-dependent RNA polymerase consist of four viral 
proteins: NP, VP35, VP30, and the polymerase, L. Characterization of the eVP35 IID 
FBP revealed that unlike the CBP, the FBP is not required for dsRNA binding or 
inhibition of IFN-β production. Instead, the present work demonstrates a critical function 
for the FBP residues in viral replication/transcription, particularly in establishing an 
essential interaction with NP. Mutagenesis studies showed that either alanine or 
glutamic acid substitution mutants to the FBP residues R225, K248, and K251 resulted 
in the loss of minigenome activity. In contrast, mutations from either lysine to arginine or 
arginine to lysine had no effect on minigenome activity indicating that the basic nature of 
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these residues is sufficient to support the polymerase cofactor function of eVP35. 
Consistent with these findings, the minigenome defective eVP35 mutants lost their 
ability to interact with NP. It has been well established in the literature that VP35 and NP 
form a critical interaction (Becker et al. 1998; Muhlberger et al. 1998; Watanabe et al. 
2006; Shi et al. 2008), resulting in a current working model that assumes VP35 binds to 
both NP and L, and in doing so, structurally bridges the polymerase and its template 
together. However, additional studies are required to pin point the determinant factors in 
the VP35-NP interaction and to resolve the NP residues involved in the VP35-NP 
interaction. Together these results further our understanding of the protein-protein 
interactions that establish the EBOV polymerase complex, in particularly the eVP35-NP 
interaction, and our data supports the current model in that the loss of the VP35-NP 
interaction exhibited by the FBP mutants results in loss of minigenome activity.  
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2.5 Figures 
 
Figure 2.1. Highly conserved basic residues within eVP35IID are localized to the 
FBP and the CBP. (A) Ribbon representation of eVP35 IID WT (PDB ID: 3FKE) 
highlighting FBP residues (left) and CBP residues (right). (B) Corresponding 
electrostatic surface representation of the FBP and the CBP (scale, -10 kT/e to +10 
kT/e).  
 
  
  
 
Figure 2.2. Mutations to the FBP residues do not significantly perturb the overall structure of eVP35 IID. 1H/15N 
HSQC spectra were collected for eVP35 IID (A) WT (black), and FBP mutants proteins (B) R225A (blue), (C) K248A (red), 
and (D) K251A (green) on a Bruker Avance II spectrometer [700.13MHz]. Spectra were overlaid with VP35 IID WT in 
NMRView and revealed minimal chemical shift perturbations. 
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Figure 2.2 continued. 
 
Figure 2.2. Mutations to the FBP residues do not significantly perturb the overall structure of eVP35 IID. 1H/15N 
HSQC spectra were collected for eVP35 IID (A) WT (black), and FBP mutants proteins (B) R225A (blue), (C) K248A (red), 
and (D) K251A (green) on a Bruker Avance II spectrometer [700.13MHz]. Spectra were overlaid with VP35 IID WT in 
NMRView and revealed minimal chemical shift perturbations. 
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Figure 2.3. eVP35 IID FBP mutants retain ability to bind dsRNA. ITC binding 
isotherms and corresponding raw data for 8-bp dsRNA binding to VP35 IID (A) WT, (B) 
R225A, (C) K248A, and (D) K251A. The corresponding average KD values for WT, 
R225A, K248A, and K251A are 0.7, 1.0, 2.4, and 0.8 µM, respectively.  
 
50 
 
Figure 2.4. Schematic model for the EBOV minigeone assay. The EBOV 
minigenome is constructed by flanking a reporter gene (GFP-CAT or luciferase, shown 
in yellow) with the 3' and 5' EBOV leader and trailer sequences (dark grey) which 
contain the necessary cis-acting elements required by the EBOV replication complex. 
The EBOV polymerase complex is reconstituted by transfecting of plasmids for viral 
proteins NP, VP35, VP30 and L in the presence of the minigenome. Co-transfected is a 
plasmid that expresses firefly luciferase from an RNA polymerase II promoter, and the 
reporter gene activity is normalized to the firefly luciferase activity. If the EBOV proteins 
are able to come together and form a functional polymerase complex, the minigenome 
serves as a template for both replication and transcription ultimately resulting in the 
expression of luciferase, which provides the readout for minigenome activity.   
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Figure 2.5. Three out of four eVP35 FBP residues are critical for polymerase 
cofactor function. Alanine substitution mutants were generated for the FBP residues 
K222, R225, K248, and K251A and tested in the EBOV minigenome assay. In the 
absence of VP35 (empty vector, -) no minigenome activity in observed. Increasing 
concentration (63ng, 125ng, and 250ng) of VP35 WT or mutant plasmids were 
transfected into cells, and 250ng was identified as the optimal concentration and set to 
100% minigenome activity. Alaline substituion mutants for eVP35 R225, K248, and 
K251 resulted in loss of minigenome activity. Error bars represent 1 standard deviation 
for three experiments. Cell lysates were Western blotted (WB) for VP35 expression 
(lower panel).  
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Figure 2.6. The basic charge of the eVP35 FBP residiues is the determinant for 
functionality in minigenome assay. In the absence of VP35 (empty vector, -) no 
minigenome activity is observed. (A) Glutamic acid substitution mutants for FBP 
residues R225, K248, and K251 lost their polymerase cofactor function. Increasing 
concentration (63ng, 125ng, 250ng, and 500ng) of VP35 WT or mutant plasmids were 
transfected into cells, and 250ng was identified as the optimal concentration and set to 
100% minigenome activity. (B) eVP35 mutants R225K, K248R, and K251R maintained 
the ability to support minigenome activity. 125ng, 250ng, 500ng of eVP35 WT or mutant 
plasmids were transfected into cells, and data were expressed as the fold induction over 
empty vector. Error bars represent standard deviations, and the lower panel for both (A) 
and (B) show the corresponding Western blots (WB) for eVP35.  
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Figure 2.7. Replication defective eVP35 FBP mutants lose their ability to interact 
with NP. (A) Cells were transfected with NP in the absence (-) or presence of full-length 
eVP35 WT or mutant proteins. Cell lysate was immunoprecipitated using anti-VP35 
antibody and proteins were detected using  anti-MBP (α-MBP) and anti-NP (α-NP) 
antibodies. (B) MBP alone or MBP-tagged eVP35 IID WT or mutant proteins were 
immobilized on amylose resin and assessed for their ability to pulldown NP from 
clarified lysate of NP expressing cells. Proteins were detected as describe in (A). (C) 
MBP-eVP35 IID WT or mutant proteins were incubated with lysate of NP expressing 
cells in the absence (-) or presence of increasing amounts of poly I:C (16nM, 98nM). 
MBP-eVP35 IID was immobilized on amylose resin and proteins were detected as 
described in (A).  
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Figure 2.8 eVP35 IID mutants retain ability to interact with EBOV L. (A) Cells were 
transfected with HA-tagged EBOV L 1-505 in the absence (-) or presence of full-length 
eVP35 WT or mutant proteins. Cell lysate was immunoprecipitated using anti-VP35 
antibody and proteins were detected using  anti-MBP (α-MBP) and anti-HA (α-HA) 
antibodies. Whole cell extract (WC). 
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CHAPTER 3. APTAMERS IN VIROLOGY 
  
This chapter is adapted from a review published in Frontiers in Microbiology.  
 
Jennifer M. Binning, Daisy W. Leung, and Gaya K. Amarasinghe. (2012). "Aptamers in 
virology: recent advances and challenges." Front Microbiol 3: 29. 
 
 I wrote the initial draft of the review and figures with input and advice from Dr. Gaya 
Amarasinghe and Dr. Daisy Leung.  
 
3.1 Introduction 
Owing to it multiple functions and interaction partners necessary to carry out 
innate immune suppression and viral replication, VP35 is a potential, and promising, 
therapeutic target. In order to target VP35 and inhibit known VP35 functions, our lab has 
employed two approaches using both small molecules and RNA aptamers. In the 
context of this dissertation, I will focus on the later, and in this chapter highlight the utility 
and advances of aptamers in virology. Aptamers are in vitro selected nucleic acid 
molecules that bind to a broad range of targets with high affinity and specificity. The 
basic isolation process, termed 'systematic evolution of ligands by exponential 
enrichment' or SELEX (Ellington et al. 1990; Robertson et al. 1990; Tuerk et al. 1990), 
utilizes a large initial pool of randomized nucleic acids from which high affinity binders 
are isolated and enriched through subsequent rounds of selection (Figure 3.1). Most 
aptamers characterized to date are single stranded DNA or RNA molecules ranging 
from 20-90 bases that can bind targets ranging from a few atoms (small molecules) to 
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many atoms (macromolecules) to intact cells and viruses. These single stranded 
polynucleotide sequences can fold into a variety of secondary structural elements, 
including double stranded RNA (dsRNA) or dsDNA, stem loops, pseudoknots, kinks, 
and bulges, providing multiple recognition surfaces for target binding.  
Aptamers are often compared to antibodies, due to the high specificity for their 
targets. However, aptamers have notable advantages over antibodies, including low 
immunogenicity and the potential for chemical derivatization to enhance in vivo stability 
and bioavailability (Jellinek et al. 1995; Chelliserrykattil et al. 2004; Kato et al. 2005). 
The aptamer selection process can be carried out in as little as 2-4 weeks, which is 
significantly shorter than antibody development, which can take on the order of months. 
The general SELEX principles guiding the selection process have remained largely 
unaltered. However, identified aptamers can be further optimized using biased libraries 
and counter selection strategies that result in aptamer subpopulations with higher 
specificity and/or affinity and other desirable characteristics, such as enhanced stability 
or membrane permeability. In addition, facile generation of modified aptamers allows for 
coupling of diagnostic tags, which can extend the use of aptamers through prolonged 
lifetimes in serum. Given the traditional comparisons with antibodies, the utility of 
aptamers in the clinic is taking longer than anticipated from the outset of discovery. 
Nonetheless, with the 2004 FDA approval of pegaptanib, an aptamer-based drug used 
to treat wet age-related muscular degeneration, and others in the pipeline, it is clear that 
aptamers will continue to contribute to our understanding of normal and aberrant cellular 
processes as well as disease treatment. Recent comprehensive reviews highlight 
advances in basic research (James 2001; James 2007; Syed et al. 2010; Sun et al. 
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2011) and clinical settings (Bunka et al. 2006; Gopinath 2007; Gopinath 2008; Meyer et 
al. 2011). These developments have positioned aptamers to make a significant impact 
in many areas.  
3.2 Aptamers in therapeutics 
The host-viral interface has become an increasingly popular target for aptamers 
because interactions between nucleic acids and proteins are critical to viral replication 
(Figure 3.2). Although not a prerequisite, targeting nucleic acid binding proteins by 
aptamers has a high probability of success due to the presence of basic surface 
charges on most nucleic acid binding proteins. The remaining sections in this chapter 
summarize select studies in order to highlight the use of aptamers against viral 
components and discuss challenges and future prospects of the field.  
By targeting essential viral proteins, aptamers provide a means for developing 
therapeutic agents to counter viral infections. Aptamers can potentially inhibit viral 
infectivity at any stage in the viral replication cycle (Figure 3.2). Attempts to target 
human immunodeficiency virus (HIV) through the use of aptamers has been of interest 
for a number of groups, and has yielded multiple aptamers which target various HIV 
proteins and various stages within the viral replication cycle (Held et al., 2006). In order 
to target HIV entry into helper T-cells, aptamers were generated against the HIV 
glycoprotein 120 (gp120). The anti-gp120 aptamers, B40, binds gp120 and in doing so 
competes with the HIV co-receptor, CCR5. The aptamer binding site is located in a 
highly conserved region of gp120, thereby, allowing neutralization of a broad range of 
HIV isolates by disrupting the gp120-CCR5 interaction (Dey et al. 2005; Dey et al. 
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2005). Additionally, binding to a conserved region of gp120 is critical due to the 
propensity of HIV to undergo mutagenesis that results in drug resistance.  The anti-
gp120 aptamer has not been approved for clinical trials, but  has been used as a basis 
for developing chimeric aptamers (Neff et al. 2011; Wheeler et al. 2011; Zhou et al. 
2011). Coupling of siRNA and the anti-gp120 aptamer through phi29 packaging RNA 
allows incorporation of two functions into one molecule (Zhou et al. 2011). The anti-
gp120 aptamer has an inhibitory effect, while the siRNA downregulates the expression 
of its target.  
Viral entry of human cytomegalovirus (HCMV) has also been targeted via 
aptamers (Wang et al. 2000). Aptamers generated against HCMV virus particles was 
carried out without prior information on specific targets. Two aptamers, L13 and L19, 
were isolated which inhibited HCMV plaque formation and growth. The antiviral activity 
of L13 and L19 aptamers identified HCMV glycoproteins B and H as targets, 
respectively, by binding to the glycoproteins and blocking viral entry (Wang et al. 2000). 
Viral RNA-dependent RNA polymerases have been a common target because 
viral polymerases use RNA as the template during genome replication. For example, 
the Hepatitis C virus (HCV) polymerase nonstructural protein 5B (NS5B), is required for 
transcribing the HCV genome and has been used to generate both anti-NS5B RNA and 
DNA aptamers (Biroccio et al. 2002; Bellecave et al. 2003; Bellecave et al. 2008). Both 
sets of aptamers have been shown to bind to NS5B with high affinity and inhibit 
polymerase activity. The mechanism of inhibition of the anti-NS5B RNA aptamer is non-
competitive with regards to the template RNA, and mutagenesis studies revealed that 
the aptamer binding site is localized to a basic patch within the thumb domain of NS5B 
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(Biroccio et al. 2002). On the other hand, two DNA aptamers were identified with one 
anti-NS5B DNA aptamer inhibiting replication by competing with the RNA template; the 
other inhibiting through a non-competitive mechanism in which initiation and post 
initiation events are disrupted. RNA aptamers capable of inhibiting NS5B polymerase 
activity were further optimized through the use of deletion clones and point 
mutagenesis, which identified a GC-rich motif and a stem-loop with a bulge as important 
features for aptamer binding to NS5B (Kanamori et al. 2009).  
In the context of HIV pathogenesis, the viral reverse transcriptase (RT) converts 
the single stranded RNA (ssRNA) viral genome into dsDNA. tRNA aptamers that target 
HIV-RT effectively inhibit the synthesis of cDNA (Tuerk et al. 1992). The ligand 1.1 
aptamer targets the HIV-RT, and is postulated to reduce adverse side effects, a main 
concern with current HIV-RT drugs, such as 3'-azido-3'-deoxythymidine (AZT) and 
dideoxyinosine. Moreover, by targeting an enzyme early in the HIV-1 replication cycle, 
the likelihood that mutations will arise resulting in drug-resistance should diminish. 
These factors make aptamers generated against HIV-RT promising candidates for drug 
development. 
Inhibition of protein translation is a key host defense mechanism against viral 
infections since viruses are completely dependent on the host machinery for protein 
synthesis. However, viruses have developed various means to evade host defenses 
and hijack the host translational machinery. For example, the HCV mRNA has an 
internal ribosome entry site (IRES), a structured region within the mRNA that binds the 
ribosome and initiates cap-independent translation, allowing HCV to circumvent the 
requirement for host initiation and elongation factors. Aptamers targeting the HCV IRES 
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inhibit IRES-dependent translation of HCV proteins (Aldaz-Carroll et al. 2002; Kikuchi et 
al. 2003; Da Rocha Gomes et al. 2004; Kikuchi et al. 2005). Furthermore, many of these 
HCV IRES aptamers inhibit translation both in vitro and in vivo, highlighting the potential 
therapeutic value of these aptamers since they target RNA secondary structures that 
are characteristic of select viral mRNAs but not host mRNA. Therefore, such selection 
may result in a reduction of negative side effects. The viral inhibitory properties of HCV 
anti-IRES aptamers can be enhanced through conjugation to other aptamers, which 
target different binding sites within the HCV IRES. This results in a conjugated anti-
IRES aptamer that binds the HCV IRES with a higher affinity and is functionally more 
effective than the unconjugated aptamers (Kikuchi et al. 2009).  Alternatively, HCV anti-
IRES aptamers can be coupled to the hammerhead ribozyme to prevent translation. 
The chimeric RNA molecule, HH363-50, inhibits IRES-dependent translation in vitro 
likely through disruption of 80S complex formation with no effect on IRES-independent 
translation. HH363-50 also reduced the level of HCV RNA due to the ribozyme activity 
of the molecule (Romero-Lopez et al. 2009).   
   
3.3 Aptamers in viral diagnostics 
Early and reliable detection of pathogens is a critical step in the successful 
treatment of infection. Due to many potential advantages aptamers provide, aptamers 
are ideal tools for diagnostics. Many examples of aptamers as a detection tool have 
been described. These studies include simple modifications to the enzyme linked 
immunosorbent assay (ELISA) as well as more complex diagnostic systems, such as 
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those that use inhibitory aptamers to suppress multiturnover enzymes (Zhou et al. 
2010). 
 The Influenza A virus hemagglutinin (HA) and neuraminidase (NA) antigens are 
glycoproteins found on the surface of the viral particle, and serve important roles in host 
membrane fusion.  A number of aptamers have been isolated against Influenza A HA 
that inhibit viral infectivity (Jeon et al. 2004; Misono et al. 2005; Gopinath et al. 2006; 
Dhar et al. 2009; Park et al. 2011). In addition to disrupting viral HA-mediated 
membrane fusion, the P30-10-16 aptamer can distinguish between closely related 
Influenza A strains. This aptamer property is novel, considering that most monoclonal 
antibodies against HA have been unsuccessful at differentiating among influenza 
subtypes. Development of these aptamers for viral subtype diagnostics will provide a 
significant advancement in our ability to differentiate highly pathogenic influenza strains 
from those that are less virulent. Further biophysical characterization to examine how 
this aptamer is able to differentiate between closely related influenza strains will likely 
yield important insights into its mechanism of action. 
 During hepatitis B viral (HBV) infection, the hepatitis B virus surface antigen 
(HBsAg) is found on the membrane of HBV-infected hepatocytes. An aptamer targeting 
HBsAg, HBs-A22, was fluorescently labeled and used to isolate cells expressing 
HBsAg. Use of fluorescence microscopy showed that that anti-HBsAg aptamer bound to 
the HBsAg-positive cell line (HepG2.2.15) but not to the HBsAg-negative cell line 
(HepG2). These results establish the use of aptamers for imaging, but also provide the 
first HBV specific antigen aptamer that could be used for early detection and treatment 
of HBV-infected cells (Liu et al. 2010).  
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Aptamers can also function as diagnostic tools when coupled to existing 
biosensors (Davis et al. 1998; Jhaveri et al. 2000; Fang et al. 2001; O'Sullivan 2002). 
Biosensors utilize a biological recognition element, such as aptamers, and a 
physiochemical transducer for easier detection and quantification.  An aptamer based 
biosensor, or aptasensor, was isolated against the trans-activator of transcription (Tat) 
of HIV-1, which is important for regulating the early phases of HIV-1 infection (Chang et 
al. 1997; Mucha et al. 2002). The Tat aptasensor was generated by immobilizing the 
aptamer on a piezoelectric quartz-crystal, the physiochemical transduction component 
of the aptasensor. Comparison of the Tat aptasensor to a corresponding immunosensor 
that uses an anti-Tat monoclonal antibody showed that the two biosensors are similar in 
terms of sensitivity and reproducibility.  Although the sensitivity of the aptasensor does 
not allow for detection of Tat in sera and cell culture supernatants, this methodology 
further establishes the potential use of aptamers in the generation of biosensors 
(Minunni et al. 2004; Tombelli et al. 2006). Further development of the aptasensors 
incorporating more stable chemical derivatives will likely overcome some of the current 
limitations of the aptasensors.    
A multicomponent reporter system consisting of an inhibitory aptamer bound to a 
restriction endonuclease and a target complement/trigger system was successful in 
differentiating Dengue virus serotypes (Fletcher et al. 2010). One of the key advantages 
of this method is that the same aptamer/enzyme complex can be used since only the 
nucleic acid complement/trigger needs modification to detect new targets. Such a 
system can be more sensitive due to the multiturnover nature of the endonuclease. 
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Further development of these aptasensors and incorporating more stable chemical 
derivatives will likely overcome some of the limitations of current aptasensors.    
  
3.4 Aptamers in basic research 
 In addition to diagnostic and therapeutic applications, aptamers can be used as 
laboratory reagents in a number of biochemical and cell-based assays, similar to 
antibodies. Aptamers have key advantages over antibodies in that they often have 
higher affinity and specificity for their targets with some binding constants (KD) <1 nM, 
which results in an enhanced signal-to-noise ratio. Additionally, aptamers can be 
generated against almost any target ranging from small organic molecules to proteins to 
whole cells (Jayasena 1999), and they are often times smaller than antibodies (7-30 
KDa for aptamers vs. ~150 KDa for antibodies) allowing them to bind regions 
inaccessible to antibodies.  
 Utilizing aptamers that disrupt protein-protein interactions, one can begin to 
dissect and characterize cellular pathways. The human T-cell leukemia virus type 1 Tax 
protein is a trans-activator that regulates the expression of various viral and cellular 
genes. Tax cannot directly bind DNA in the absence of certain host transcription factors, 
suggesting that protein-protein interactions are essential for Tax function. The YT1 
aptamer disrupts Tax interactions with the cyclic AMP-response element binding protein 
(CREB) and NF-kappaB, but not serum response factor (SRF), all of which are known 
to interact with Tax proteins (Tian et al. 1995). These results suggest that the CREB 
and Nf-kappaB binding interfaces on Tax may potentially overlap or are in close 
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proximity, whereas the SRF binding site occupies a different surface on Tax. Therefore, 
aptamers provide a potential tool to map interaction surfaces between binding partners.  
  Assembly of the viral nucleocapsid (NC) requires multiple protein-protein and 
protein-nucleic acid interactions. The HIV NC is a highly conserved protein that plays a 
key role in RNA encapsidation and viral replication, and specifically binds viral genomic 
RNA through a unique sequence termed the psi (Ψ).  An aptamer generated against NC 
competes with the psi sequence and prevents proper encapsidation of the viral genome, 
which likely inhibits proper packaging of the genomic RNA (Kim et al. 2002). Other HIV-
1 NC aptamers against the HIV-1 Gag protein bind the matrix and the NC domains of 
Gag and reduced HIV replication in cultured cells. The inhibitory effect of these 
aptamers was not due to a defect in virion release but to the downregulation of 
intracellular Gag protein and mRNA. A subset of aptamers which specifically bound NC 
competes with the psi packing signal of HIV-1, and disrupts interactions between Gag 
and viral RNA (Ramalingam et al. 2011). Unlike other aptamers that inhibit early stages 
in viral infection, the NC aptamer targets events that occur after viral entry, and 
therefore, allows one to study the intracellular effects of viral infection. 
 Using aptamers to specifically target and modulate functions of proteins within 
cellular pathways or the viral replication cycle can provide invaluable information about 
these respective systems. Nonetheless, an additional advantage of using aptamers to 
investigate cellular signaling is the ability to selectively turn the aptamers “on” and “off” 
with effectors. Further advances in the spatial and temporal regulation of aptamers will 
be important for enhancing our understanding of viral/host interactions. The potential 
regulation of aptamers with effector molecules is highlighted by Vuyisich et al. in the 
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regulation of formamidopyrimidine glycosylase (Fpg), a bacterial enzyme involved in 
DNA repair (Vuyisich et al. 2002).  A modified SELEX protocol was used where RNA-
bound Fpg was treated with neomycin in order to elute the bound RNA.  The Fpg 
aptamer inhibited Fpg activity, but the functionality was restored in the presence of 
neomycin.  Rusconi et al. utilized anti-sense RNA in order to regulate the function of an 
aptamer targeted against the blood coagulation factor IXa (Rusconi et al. 2002).  The 
anti-sense RNA base pairs to complementary regions within the aptamer and disrupts 
aptamer function.  The factor IXa aptamer and anti-sense RNA antidote pair was an 
effective, reversible anticoagulant and shows potential for clinical application.  
 
3.5 Conclusions 
Many viral proteins, in particularly  filoviral proteins, bind nucleic acids, which 
makes them  ideal targets for aptamer development. As outlined above, aptamers have 
been used in various studies to characterize and counter host-viral interactions. For 
example, an aptamer targeting the HIV-1 Tax protein was able to differentiate Tax 
binding to specific transcription factors. Similarly, aptamers can be used to dissect 
protein-protein interfaces and to validate targets for small molecules. An advantage 
aptamers have over small molecules is their ability to be identified against a target 
without a priori knowledge of the exact site or target.  Similarly, aptamers can be used in 
target validation, a particularly important area where aptamers can potentially provide a 
distinct advantage. Current selection of small molecules often depend on the availability 
of validating functional assays, structural and biochemical data, prior to initiating drug 
discovery efforts. Such efforts inherently consume large amounts of time and resource. 
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In contrast, one can develop aptamers towards a target with a fraction of the cost and 
time. However,  many of the above examples have limited knowledge on the structural 
and biochemical aspects of these aptamer/target interactions, and available data are 
primarily restricted to secondary structure predictions or mapping. The addition of 
structural and biochemical studies of aptamer/target pairs can enhance the utility of 
these aptamers by providing new information on the binding interfaces and by providing 
information for structure-based optimization of aptamers. Continuing development and 
optimization of multifunctional and chimeric aptamers, and development of aptamer 
libraries for strain specific viral identification and coupling of aptamers to more sensitive 
detection methods will lead to more broadly applicable therapeutic and diagnostic 
applications in the future.  
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3.6 Figures 
 
Figure 3.1 The SELEX process. An initial pool of dsDNA is in vitro transcribed into 
RNA. The resulting pool of RNA is subject to (A) counter selection to remove non-
specific binders. (B) RNAs that binds to the target are selected by filter binding. (C) RNA 
bound to the membrane is recovered, reverse transcribed and amplified by PCR. (D) 
The resulting DNA pool is further subject to another round of SELEX for enrichment or 
cloned and sequenced. 
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Figure 3.2 Key steps in the viral replication cycle are potential targets for aptamer 
development.  Aptamers have been generated to target viral proteins found in both the 
extracellular and intracellular space. Examples of viral proteins with existing aptamers 
are identified in red type. 
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CHAPTER 4. DEVELOPMENT OF RNA APTAMERS  
TARGETING EBOLAVIRUS VP35 
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4.1 Introduction 
 Negative stranded RNA viruses possess a limited number of open reading 
frames (ORFs), such that many of the encoded proteins function at multiple stages of 
the viral replication cycle. The multifunctional nature of these viral proteins potentially 
provides several opportunities to develop antivirals. However, target validation of non-
enzymatic viral proteins is particularly challenging as inhibitors must be identified de 
novo. Innovative methods that combine structure/function information can provide 
critical target validation prior to initiation of more effective small molecule-based 
methods. 
 Development of inhibitors that target key components in pathogens often 
requires detailed knowledge of structure and function or screening of large compound 
libraries with highly sensitive reporter(s). Nucleic acid aptamers provide an alternative 
method for inhibitor development as well as target validation (Lee et al. 2006; Kang et 
al. 2012). Aptamer identification and characterization does not require detailed 
knowledge of the target (Wang 2009; Bunka et al. 2010; Soontornworajit et al. 2011; 
Binning et al. 2012). However, in situations where detailed structural and functional 
information are available, aptamer development can be tailored to enhance the impact 
of aptamer binding by targeting aptamer interactions to functionally important regions. 
Using such an approach, here we report the development of aptamers against eVP35 
IID. Previous structural and functional results were utilized to identify functionally 
relevant regions of VP35 to target for aptamer development. Aptamers were identified 
using SELEX (Ellington et al. 1990; Tuerk et al. 1990) methods by targeting WT eVP35 
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IID and a mutant form of the protein. Two aptamers, representing two distinct binding 
modes, were selected for further characterization. These studies revealed that one 
aptamer (1G8-14) preferentially binds EBOV and RESTV VP35 IID proteins, while the 
other (2F11-14) binds both EBOV and MARV VP35 IID proteins. Using in vitro studies, 
we demonstrate the utility of our selected aptamers as potential inhibitors, which can 
disrupt a critical protein-protein interaction in the filoviral replication complex and the 
activity of the minigenome system in cells. Taken together, our results suggest that 
aptamers identified here are valuable reagents for basic research and target validation 
of filoviral VP35 proteins for antiviral development.  
 
4.2 Materials and Methods 
Protein expression and purification. Mutant eVP35 IID proteins were generated by 
overlap PCR and the plasmids were sequenced to confirm the mutation(s). 
Recombinant eVP35 IID WT and mutant proteins were expressed as previously 
described (Leung et al. 2010; Ramanan et al. 2012). The integrity of the proteins was 
assessed by 1H/15N-HSQC NMR spectra.  
 
Crystallization and structure determination. Initial crystallization conditions for 
eVP35 IID CBP3mut (where CBP residues R312, K319, and R322 are mutated to 
alanine) and FBP4mut (where FBP residues K222, R225, K248, and K251 were 
mutated to alanine) were identified using commercially available crystallization screens 
(Hampton Research), and in-house optimized native crystals were grown at 25 °C using 
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the hanging-drop vapor diffusion method. eVP35 IID CBP3mut (16.4 mg/mL) was 
diluted in a 1:1 ratio with reservoir solution containing 2.2 M Na/K phosphate (pH 4.5). 
eVP35 IID FBP4mut (24 mg/mL) was diluted in a 1:1 ratio with reservoir solution 
containing 0.2 M MgCl2, 0.1 M HEPES (pH 7.5), 30% PEG 400. Crystals were soaked in 
reservoir solution containing 25% glycerol and vitrified in liquid nitrogen. Diffraction data 
was collected at Advanced Photon Source (Sector 19) at 100 K (Table 1). One hundred 
and eighty frames of data were collected with a frame width of 1.0° and detector-to-
crystal distance of 300 mm for eVP35 IID FBP4mut. 450 frames of data were collected 
with a frame width of 0.2° and detector-to-crystal distance of 250 mm for eVP35 IID 
CBP3mut. Diffraction data were indexed, scaled and merged using HKL-3000 
(Otwinowski et al. 1997). Intensities were converted to structure factors using CCP4 
(Collaborative Computational Project 1994). The structures were solved using molecular 
replacement, with chain B from eVP35 IID crystal structure (PDB ID 3FKE) as the 
search model using MOLREP(Collaborative Computational Project 1994). The 
structures were refined using REFMAC5 (Murshudov et al. 1997) and PHENIX (Adams 
et al. 2010). Addition of solvent molecules and manual model building was performed 
using Coot (Emsley et al. 2004). TLS parameters were refined using the TLMSD server 
(Painter et al. 2006). Final validation was performed using MOLPROBITY server (Chen 
et al. 2010). 
 
In vitro selection of aptamers. In vitro SELEX selection of aptamers was carried out 
using eVP35 IID wildtype (WT) and eVP35 IID CBP3mut as targets (Fitzwater et al. 
1996; Jhaveri et al. 2001).  Oligonucleotide templates and primers were chemically 
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synthesized with standard desalting by Integrated DNA Technology (Coralville, IA). The 
dsDNA library was generated from a ssDNA library (5`-
GCCTGTTGTGAGCCTCCTGTCGAA(N45)TTGAGCGTTTATTCTTGTCTCCC-3`). 
Using the dsDNA library as a template, RNAs were in vitro transcribed following 
established protocols. The transcribed RNA was purified by phenol/chloroform 
extraction followed by ethanol precipitation and separated out on a 7M urea-8% PAGE. 
Purified RNAs were incubated with either eVP35 IID WT or eVP35 IID CBP3mut at 
37°C for 0.5 to 1 hr in 10 mM HEPES (pH 7.0), 150 mM NaCl, 2mM TCEP (tris(2-
carboxyethyl)phosphine), and 1 mM MgCl2 and filtered through nitrocellulose membrane 
(Millipore). The protein-bound RNA was eluted with 7M urea, precipitated by ethanol, 
and reverse transcribed using SuperScriptTM reverse transcriptase (Invitrogen).  The 
reverse transcribed cDNAs were amplified by polymerase chain reaction (PCR) using 
oligo-003 (5`-TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-3`) and 
oligo-004 (5`-GCCTGTTGTGAGCCTCCTGTCGAA-3`). In vitro transcription, RNA-
protein binding, partition, and RT-PCR were repeated for 14 rounds and the resulting 
binders at rounds 10 and 14 were subcloned into the pCR-XL-TOPO vector (Invitrogen) 
for sequencing. Negative selection was carried out against the nitrocellulose membrane 
at rounds 3, 6, 9, and 12 to reduce non-specific interactions. The protein concentration 
for eVP35 IID WT was decreased from 0.4 µM at round 1 to 0.025 µM by round 14 in 
order to enhance selection stringency. For eVP35 IID CBP3mut, the protein 
concentration was decreased from 4 µM at round 1 to 0.05 µM by round 14. The 
concentration of protein used in each selection was adjusted so that the we can obtain 
about 1% retention of aptamers during each selection. Thus, the initial values of 0.4 µM 
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for selection against eVP35 IID WT and 4 µM for selection against eVP35 IID CBP3mut 
were determined through this process. 
 
End labeling of dsRNA and aptamers. 32P 5`-end labeling of RNAs was carried out at 
37°C for 1.5 hrs in a 20 μl reaction containing 70 mM Tris (pH 7.6 at 25°C), 10 mM 
MgCl2, 5 mM DTT, 1U/μl T4 polynucleotide kinase (New England Biolabs), 1 μM γ-ATP 
(Perkin Elmer), 5 μM RNA. 32P 3`-end labeling of RNA  was carried out at 16°C for 18 hr 
in a 30 µl reaction of 50 mM Tris-HCl (pH 7.8 at 25°C), 10 mM MgCl2, 10 mM DTT, 1 
mM ATP, 10% DMSO, 0.67 U/µl T4 RNA ligase 1 (New England Biolabs), 2 μM 32P -
cytidine-3`,5`-bis-phosphate (32pCp), 5 μM RNA (dsRNA or aptamer) (Peters et al. 
2006). Labeled RNAs were separated on a 7M urea-8% PAGE and eluted by crush 
soak method.   
 
Filter binding assays for binding and competition assays for eVP35 IID-aptamer 
interaction. Filter binding assays were carried out as reported previously (Ramanan et 
al. 2012). For dissociation constant (KD) measurements, the reaction mixtures contained 
1-2 nM 32P-aptamer or 32P-dsRNA and eVP35 IID protein ranging from 0-100 µM. For 
single binding point assays, the reaction mixtures contained 10 nM 32P-aptamer and 0.5 
µM eVP35 IID proteins. In the competition assay, the reaction mixtures included 10 nM 
32P-aptamer, 0.5 µM eVP35 IID or 10 nM 32P-dsRNA, 10 µM eVP35 IID and unlabeled 
aptamer or dsRNA ranging from 0-20 µM. All reaction mixtures were incubated at 25°C 
for 15 min. Binding experiments were carried out in buffer containing 10 mM HEPES 
(pH 7.0), 150 mM NaCl, 2mM TCEP, 1 mM MgCl2 in 50 μl reactions in a 96-well 
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vacuum filtration apparatus assembled with a nitrocellulose membrane on top of a 
positively charged nylon membrane. Membranes were washed and air-dried before 
exposure for 12-16 hrs along with a calibration standard, scanned on a Typhoon 9410 
Variable Mode l Imager in phosphor storage mode, and quantified by ImageQuant (GE 
Healthcare). The ratio of the intensity on nitrocellulose membrane to that of the sum on 
nitrocellulose membrane plus nylon membrane was expressed as fractional binding. 
The binding curves were fit to the equation B=Bmax*[M] /(KD+[M]) using ORIGIN 7.0 
software (OriginLab), where B is the fraction bound, Bmax is the maximum fractional 
binding, [M] is the protein concentration, and KD is the dissociation constant. 
Competition curves were fitted to the equation B/B0= 1/(1+[M]/IC50)
n), where B is the 
fraction of 32P-labeled aptamers bound to nitrocellulose membrane at different 
concentrations of competitors (aptamer or dsRNA), B0 is fraction of 
32P-labeled 
aptamers bound to nitrocellulose membrane without any competitors, [M] is the 
competitor concentration, IC50 is the concentration where 50% competition occurs, and 
n is a constant.  
 
Isothermal titration calorimetry (ITC). Quantitative analysis of eVP35 IID protein-
aptamer interactions were performed on a VP-isothermal titration calorimeter (VP-ITC) 
(Microcal). Protein samples were dialyzed against 500 mL of buffer containing 10 mM 
HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl2, and 2 mM TCEP for 12 h at 25 °C. 
Aptamer stocks were diluted >200-fold with dialysis buffer. The syringe contained 
eVP35 IID proteins at 100 to 150 µM, and the cell contained aptamers (1G8-14, 2F11-
14) at 3 to 5 µM. ITC titrations were carried out using a reference power of 5 µcal/sec. 
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The resulting ITC data were processed and fit to a one-site binding model or a two-site 
binding model to determine n (number of binding sites) and KD (dissociation constant) 
using ORIGIN 7.0 software. Both one and two site binding models were considered for 
each data set, but selection of the model was based on the quality of the fits. For two 
site binding, both sequential and independent binding modes were also considered. The 
two-site binding model used in this study assumes two thermodynamically independent 
binding events.  
 
Pulldown assays. Pulldown assays were performed in buffer containing 10 mM 
HEPES (pH 7.0), 150 mM NaCl, 1 mM MgCl2, and 5 mM 2-mercaptoethanol at 25 °C. 
MBP-His tagged eVP35 IID WT or mutant proteins were immobilized on amylose resin. 
Resin bound MBP-His tagged eVP35 IID was incubated with purified His-tagged NP 
protein and subsequently washed. For aptamer competition assays, either 100 µM 
aptamer or 300 µM dsRNA was incubated with MBP-His tagged eVP35 IID prior to 
incubation with NP. The level of protein used in the assay reflects our efforts to ensure 
proper detection of the pulldown experiment. Pulldown samples were separated on 
SDS-PAGE and analyzed by Western blot using mouse anti-His antibody (Santa Cruz 
biotechnology), followed by horseradish peroxidase (HRP) conjugated goat anti-mouse 
antibody (Bio-Rad). Membranes were developed using Millipore Immobilon Western 
Chemiluminescence HRP substrate and recorded on a ChemiDoc (Bio-Rad). 
 
EBOV transcription/replication assays. The plasmids used in the EBOV 
transcription/replication assays were described previously (Muhlberger et al. 1999; 
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Leung et al. 2010; Prins et al. 2010). NP, VP35, VP30 and L proteins were cloned into 
pTM1 with only the cDNA sequence (no virus-derived UTRs were present).  Aptamers 
were cloned into a modified pSilencer  plasmid (Ramalingam et al. 2011) and the 
corresponding plasmids were sequenced to verify the accuracy of the aptamers. 
 
Quantitation of total aptamer copy number in transfected cells by qRT-PCR. 
Genome equivalent (GEq) copy numbers (total copies,) of aptamers in the minigenome 
assay were measured using primer/probes targeting the aptamers. Briefly, real-time 
PCR (RT-PCR) was performed using Superscript II RT-PCR kits (Invitrogen). All RT-
PCR mixtures contained 5 µl of RNA eluate and master mixes were set up following the 
manufacturer’s protocols.  Standards and test samples were assayed in triplicate using 
the CFX96 detection system (Bio-Rad) with the following cycle conditions: 50° C for 10 
min, 95°C for 5 min, and 40 cycles of 95°C for 10 sec and 59°C for 30 sec. Threshold 
cycle (CT) values representing aptamers were used to determine Total copies. To 
create the GEq standard, DNA from aptamers stocks (100 ng) was used and the 
number of genomes was calculated using Avogadro’s number and the total molecular 
weight of the plasmid with aptamer. 
 
Aptamer secondary structure prediction. The computational program RNAfold from 
Vienna package v.2.0 (Gruber et al. 2008) was used to predict the secondary structures 
for RNA aptamers 1G8-14 and 2F11-14. Default parameters on the RNAfold server 
were used except for the Turner Model 2004 (Mathews et al. 1999), which was used as 
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the RNA parameter source. Results were assessed for the minimum free energy (MFE) 
structure prediction as well as thermodynamic ensemble predictions, including centroid 
structure (Ding et al. 2005) and base-pairing probabilities using dot plot 
analysis(McCaskill 1990) as implemented in RNAfold. Resulting secondary structures 
for the MFE and the centroid were visualized with the RNA graphics program VARNA 
(Darty et al. 2009). 
 
Circular dichroism (CD). CD data were collected for 1G8-14 and 2F11-14 at 10 µM in 
a quartz cuvette with a 1 mm path-length using a ChirascanTM CD spectrometer. CD 
spectra were acquired from 200 to 320 nm at 5 and 95 ºC at an interval of 1 nm and 
time-per-point of 2 sec. Temperature melting of aptamers was performed by monitoring 
the ellipticity at 260 nm from 5 to 95 °C with a 2 °C increment at a 1 °C/min gradient. 
ORIGIN 7.0 software was used to plot CD spectra and to calculate first derivatives from 
the temperature melting plots. 
 
4.3 Results 
4.3.1 Mutation to FBP and CBP residues does not  
perturb the overall fold of eVP35 IID 
 The CBP and FBP contain highly conserved basic residues in VP35 IID that are 
functionally important as mutations of either the CBP or the FBP impair several VP35 
mediated functions (Leung et al. 2010). Therefore, a series of structural studies were 
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carried out to characterize the impact of these mutations on the integrity of the structure 
of eVP35 IID. The eVP35 IID FBP4mut and CBP3mut were expressed, purified, and 
concentrated to 24 mg/ml and 16.4 mg/ml, respectively, and subsequently used for 
crystallographic studies. Commercially available Hampton crystal screens were used to 
identify initial crystallization conditions using the hanging-drop vapor diffusion method. 
eVP35 IID FBP4mut initially crystallized in 0.2 M MgCl2, 0.1 M HEPES (pH 7.5), 30% 
PEG 400, yielding crystals suitable for data collection. eVP35 IID CBP3mut initially 
crystallized in 0.1 M HEPES sodium (pH 7.5), 0.8 M sodium phosphate monobasic 
monohydrate, 0.8 M potassium phosphate monobasic, and after several optimization 
steps, crystals were obtained in 2.2 M Na/K phosphate (pH 4.5), which yielded 
diffraction data suitable for structure determination of the protein (Figure 4.1). These 
studies resulted in crystal structures of eVP35 IID CBP3mut (PDB code 4IJE) and 
FBP4mut (PDB code 4IJF), which were solved to a resolution of 1.9 and 2.5 Å, 
respectively using the eVP35 IID WT (PDB code 3FKE) structure as the search model 
for molecular replacement (Table 4.1). These structures revealed minimal changes in 
the overall protein fold when compared to eVP35 IID (Figure 4.2). The most notable 
difference between the structures was observed in a short helix (α5) located within the 
β-sheet subdomain, in which the CBP3mut and FBP4mut structures make one turn of 
the helix instead of two. Comparison of the eVP35 IID WT, CBP3mut, and FBP4mut 
structures revealed that eVP35 IID CBP3mut and eVP35 IID FBP4mut structures 
display RMSD values of 0.68 and 0.46 Å, respectively, which further suggest minimal 
structural changes upon mutating out the CBP and FBP. Analysis of surface 
electrostatics, however, showed significant differences among the three structures 
88 
 
(Figure 4.3). As expected, the CBP3mut resulted in a loss of the basic charge at the 
CBP, but the FBP was relatively unaffected, while the structure of FBP4mut revealed 
that the basic charge at the FBP was lost with the CBP unaffected.  
 
4.3.2 SELEX identifies RNA aptamers that bind eVP35 IID 
 In order to generate different classes of aptamers for eVP35 IID, aptamer 
selection was carried out against two targets, eVP35 IID WT and eVP35 IID CBP3mut 
proteins using SELEX (Figure 4.7A). By using eVP35 IID WT and CBP3mut proteins, 
we biased the aptamer selection to different conserved regions of eVP35 IID. We 
expected that the dsRNA binding site formed by CBP residues would dominate aptamer 
selection using eVP35 IID WT as a target due to the highly basic charge and dsRNA 
binding properties in this region. In contrast, by mutating the CBP (in eVP35 IID 
CBP3mut), we reduced the basic nature of the CBP region with the intent that other 
charged regions, preferably the FBP, could compete during aptamer selection. The 
initial RNA pool contained RNA species of approximately 90 bases, with 45 nucleotides 
in the variable region flanked on either side by a 5` and a 3` common region. This initial 
pool bound eVP35 IID WT with a KD of 2900 ± 200 nM and bound eVP35 IID CBP3mut 
with a KD of 36000 ± 8000 nM. After several rounds of SELEX, each aptamer pool 
displayed enhanced affinity and specificity for eVP35 IID WT and eVP35 IID CBP3mut 
proteins. Our progress curves show >10-fold affinity enhancement for the final aptamer 
pool, with an affinity of 300 ± 100 nM at round 14 for eVP35 IID WT (Figure 4.4A) and 
2800 ± 600 nM at round 10 for eVP35 IID CBP3mut (Figure 4.4B). We also extended 
our selection against eVP35 IID CBP3mut up to round 14. Although this pool displayed 
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a high degree of non-specific binding to the nitrocellulose membrane, we were able to 
identify select individual aptamers from rounds 10 and 14. As discussed below, we were 
able to further characterize these select aptamers for affinity measurements and 
ranking.  
 For our initial SELEX studies, we observed significant enrichment of select 
sequences from a total of 96 clones. Using ClustalW multiple sequence alignments, 
sequences with variations less than 5% of the total aptamer length (i.e. 4 nucleotides or 
less that includes the constant/primer regions and the variable region) were grouped 
together and represented by a single member. We first selected 9 aptamers from the 1-
series and 3 aptamers from the 2-series (Figure 4.4C). Subsequently, we identified 
representative members from each group based on their affinity for eVP35 IID WT and 
their ability to inhibit the interaction between VP35 IID and NP (see below). These 
selected aptamers were subjected to further characterization and ranking based upon 
affinity measurements with the top binders from each series selected for further 
analysis. Aptamer 1G8-14 was chosen to represent the 1-series aptamers, which were 
selected against eVP35 IID WT, and aptamer 2F11-14 was chosen to represent the 2-
series aptamers, which were selected against eVP35 IID CBP3mut. In order to further 
examine RNA structural determinants, we used ViennaRNA structural prediction 
software to predict the RNA secondary structure of 1G8-14 and 2F11-14. The resulting 
secondary structure predictions for the MFE and the centroid were visualized with the 
RNA graphics program VARNA (Darty et al. 2009), and base-pairing probabilities for the 
MFE and ensemble are shown using dot plot analysis (Figure 4.5) (Murshudov et al. 
1997). Based on the structure predictions, the 1G8-14 MFE and centroid structure 
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displayed 15.12 ensemble diversity and the MFE structure represented 5.12% of the 
ensemble compared to the 2F11-14 MFE and centroid structure with 13.46 ensemble 
diversity and 4.23% of the ensemble represented by the MFE. However, the free energy 
of the ensemble for 1G8-14 was -22.63 kcal/mol compared to -12.75 kcal/mol for 2F11-
14 suggesting that the 1G8-14 aptamer may adopt a more stable structure. Our CD 
data show differences in the corresponding spectra providing some experimental 
evidence that indicate structural differences between 1G8-14 and 2F11-14 aptamers 
(Figure 4.6). However, additional studies are required to appropriately characterize the 
actual structural differences between 1G8-14 and 2F11-14 aptamers. As an initial step 
in our efforts to define the optimum aptamer, we carried out boundary determination 
studies and tested several shorter aptamers based on the results of our boundary 
determination experiments. These results are described in the section entitled "Primer 
binding region of 1G8-14 is important for high affinity VP35 IID binding" (see below). 
These studies supported the use of full length aptamers in our present studies as 
discussed below. 
 Aptamers 1G8-14 and 2F11-14 bound eVP35 IID WT with affinities higher than 
dsRNA. At 1µM protein, the fractional binding for both 1G8-14 and 2F11-14 was >0.5, 
while the fractional binding for dsRNA was <0.3 (Figure 4.7B). eVP35 IID CBP3mut 
bound to 2F11-14 with high affinity and to 1G8-14 only at higher protein concentrations 
(10 M protein) (Figure  4.7C). These binding studies provided an initial indication that 
we had identified aptamers that bind to eVP35 IID differently, with the CBP residues 
contributing to 1G8-14 aptamer binding. The ability of eVP35 IID WT and eVP35 IID 
CBP3mut to bind ssRNA and dsRNA was also assessed. As previously shown, eVP35 
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IID WT binds to dsRNA, but not ssRNA (Figure 4.7C). eVP35 IID CBP3mut does not 
bind to dsRNA due to mutations at key dsRNA binding residues, R312, K319 and R322 
(Figure 4.7C) (Hartman et al. 2004; Prins et al. 2010). Previous studies have shown 
that eVP35 binds dsRNA containing a 5`ppp moiety with higher affinity than blunt end 
dsRNA(Kimberlin et al. 2010; Leung et al. 2010). Therefore, we tested if a 5`ppp or 
5`OH affected aptamer binding to eVP35 IID. The resulting data suggest that the 5` 
phosphorylation state of the aptamer does not influence eVP35 IID binding (Figure 4.8). 
Additionally, this observation supports the notion that the eVP35-aptamer interactions 
are distinct from those observed between eVP35 IID and dsRNA (Cardenas et al. 2006; 
Leung et al. 2010). 
 
4.3.3 Aptamers recognize partially overlapping sites in eVP35 IID 
We and others have shown that eVP35-dsRNA interactions are mediated 
through the CBP region of eVP35 IID (Hartman et al. 2004; Cardenas et al. 2006; Leung 
et al. 2009; Kimberlin et al. 2010; Leung et al. 2010). Therefore, a series of basic 
residues in eVP35 IID were mutated to determine the contribution of these residues, if 
any, to 1G8-14 and 2F11-14 aptamer binding. Representative single point binding data 
for 1G8-14 and 2F11-14 aptamers revealed distinct binding patterns. 1G8-14 aptamer 
binding primarily depends on a subset of residues that are also important for dsRNA 
binding and IFN inhibition. Single mutation of residues F239, R305, K309, R312, R322, 
and K339 to alanine had little effect on the 1G8-14 aptamer binding (<30% relative to 
WT) whereas double/triple mutations (K309A/R312A, K319A/R322A, CBP3mut) 
significantly diminished binding to 1G8-14 (>70% relative to WT) (Figure 4.9). Mutations 
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of the FBP residues (eVP35 IID FBP4mut) also impair binding to 1G8-14; however, 
further experiments revealed that this decrease in 1G8-14 binding to eVP35 IID 
FBP4mut is largely due to a decrease in the maximum fractional binding and not due to 
a substantial change in binding affinity (data not shown). Moreover, these aptamers 
readily competed with dsRNA in competition assays (Figure 4.10). These results are 
different from those observed for dsRNA binding, where select single point mutation of 
residues in the CBP abolished dsRNA binding (Leung et al. 2010). Collectively, these 
results suggest that aptamer binding involves multiple residues within a given eVP35 IID 
surface, with the CBP residues providing the largest contribution towards 1G8-14 
aptamer binding. 
For the 2F11-14 aptamer, we observe a set of residues different from those 
important for 1G8-14 binding, including R225, K251, and F239, as mutation of these 
residues to alanine result in some loss of aptamer binding (<40% relative to WT) 
(Figure 4.9B). Most significantly, R305A mutant alone can drastically decrease binding 
to 2F11-14 (>70% relative to WT). In contrast to 1G8-14, eVP35 IID CBP3mut had 
limited impact on 2F11-14 binding, consistent with the single point data (Figure 4.7C). 
Residues R305 and K309 are important for both aptamers, suggesting that the aptamer 
binding sites are partially overlapping at or near these residues. 
 
4.3.4 Residues in eVP35 IID CBP and FBP contribute 
differentially to aptamer binding 
To further characterize eVP35-aptamer interactions, we measured the binding 
affinities of aptamer to eVP35 IID WT and mutant proteins using ITC. eVP35 IID WT 
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bound 1G8-14 aptamer with high affinity compared to dsRNA (Figure 4.11A) (Leung et 
al. 2010; Prins et al. 2010). One- and two-site binding models were considered, 
ultimately resulting in the ITC data being fit using a two-site binding model, indicating 
that there are two independent binding modes for eVP35 IID on 1G8-14eVP35. The first 
binding mode is of high affinity (KD,1 = 3.7 ± 0.2 nM, n1 = 1.1 ± 0.1), which we term the 
"aptamer binding mode", whereas the second binding mode showed moderate affinity 
(KD,2 = 1400± 500 nM , n2 = 2.7 ± 0.4) (Figure 4.11A, Table 4.2). The affinity and the 
multiple bindings displayed by the second binding mode suggest that this is the dsRNA 
binding mode. Mutation of residues in the FBP (e.g. K248A and FBP4mut) had little 
effect on binding (Figure 4.11B-C). When we test binding of aptamer to eVP35 IID 
proteins containing mutations of residues important for dsRNA binding (e.g. R312A and 
F239A), we find that the second binding mode is eliminated and the data can be fit to a 
one-site binding model (KD,1 values of 83 ± 10 nM and 85 ± 50 nM, respectively) (Figure 
4.11D-E). Furthermore, mutation of three CBP residues together (i.e 
R312A/K319A/R322A triple mutant or CBP3mut) or in combination with mutations of the 
four FBP residues (i.e. FBP4mut/R312A and FBP4mut/F239A) in eVP35 IID results in 
complete loss of 1G8-14 aptamer binding (Figure 4.11F-H). For the second binding 
mode, these data are consistent with previously reported descriptions of the dsRNA-
eVP35 interaction (Leung et al. 2010). Altogether, our data suggest that the first binding 
mode is the high affinity aptamer-eVP35 IID interaction (aptamer mode) and the second 
binding mode is eVP35 IID binding to double stranded regions (dsRNA mode) in the 
aptamer (Table 4.3). 
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The ITC binding data for 2F11-14 aptamer to eVP35 IID were fit to a two-site 
binding model, where KD,1 = 7.1 ± 0.1 nM (n1 = 1.2 ± 0.0) and  KD,2 = 380 ± 40 nM (n2 = 
5.1 ± 0.1) (Figure 4.12A, Table 4.2). A single point mutation in the FBP, K248A, leads 
to slightly diminished binding with an approximately 5-fold increase in KD,1 and a 2.5-fold 
increase in KD,2 (Figure 4.12B). Mutation of four residues in the FBP (eVP35 IID 
FBP4mut) leads to near complete loss of 2F11-14 binding (Figure 4.12C), emphasizing 
a critical role for the FBP in 2F11-14 aptamer binding. Mutation of residues in the CBP 
eliminates the second binding event with KD,1 = 56 ± 7 nM, KD,1 = 100 ± 8 nM, and  KD,1 
= 52 ± 6 nM for eVP35 IID CBP3mut, F239A, and R312A, respectively (Figure 4.12D-
F). Interestingly, mutation of K248A in combination with the CBP3mut leads to a ~25-
fold increase in KD,1 compared to eVP35 IID WT (Figure 4.12G), but does not abolish 
binding altogether. Thus, in contrast to 1G8-14, residues in the FBP are critical for high 
affinity 2F11-14 binding. Similar to the results observed for 1G8-14 binding, residues in 
the CBP contribute to the second binding event, presumably through contacts with 
double stranded regions of the 2F11-14 aptamer. Our results are summarized in Table 
4.3. 
In order to better define the binding interface for eVP35 IID-1G8-14 and eVP35 
IID/2F11-14, and how these aptamers are oriented with respect to eVP35 IID, we used 
a filter binding competition assay to see if 1G8-14 could compete with 2F11-14 for 
eVP35 IID binding and vice versa. As expected, unlabeled 1G8-14 was able to compete 
off 32P-labeled 1G8-14. Unlabeled 1G8-14 can also compete off 32P-labeled 2F11-14 
(Figure 4.10B-C). However, unlabeled 2F11-14 could only compete off 32P-labeled 
2F11-14, but not 32P-labeled 1G8-14. Since 1G8-14 was selected against WT eVP35 
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IID, it is conceivable that 1G8-14 aptamer would make contacts with both basic patches. 
This notion is supported by our ITC data (described above), showing that the CBP is the 
primary binding site for 1G8-14, but the FBP also contributes to 1G8-14 binding, and 
mutations to a CBP residue in combination with mutations to the FBP region (FBP4mut 
+ R312A) results in loss of interaction. In contrast, 2F11-14 aptamer, which was 
selected against a mutant protein with only the FBP present, may predominantly interact 
with the FBP surface. Altogether, these data are consistent with the notion that distinct 
classes of high affinity aptamers can be developed using eVP35 WT and mutant eVP35 
IID proteins as SELEX targets. 
 
4.3.5 Primer binding region of 1G8-14 is important for  
high affinity VP35 IID binding 
 The structure predictions for the 1G8-14 aptamer (Figure 4.5) suggested that the 
primer binding regions may be important for secondary structure. To further evaluate 
the contributions from secondary structure of the 1G8-14 primer regions, we performed 
binding site boundary measurements to identify the nucleotides of 1G8-14 important for 
binding to eVP35 IID (Figure 4.13). The resulting data suggests that the region between 
nucleotides 36 and 65 is important. However, given the nature of the experiment, it was 
not clear if this is due to binding of the structural element shown in Figure 4.13B or if 
binding was primarily driven by the sequence between nucleotides 36 to 65 (indicated 
by arrows in Figure 13C). In this assay, we used partially digested aptamers under 
native conditions and isolated aptamer fragments that bound eVP35 IID binding. RNA 
bound eVP35 IID proteins were subsequently subjected to denaturing gel 
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electrophoresis for sequence mapping. In order to differentiate between the two 
potential aptamer fragments that form the high affinity binding, we generated the 
minimum RNA sequence (nucleotides 36-65) and subjected that sequence to structure 
predictions and binding studies. In addition, we also tested RNA fragments 
corresponding to 1-65 and 36-90 nucleotides. These predictions revealed that bases 
36-65 forms a stem-loop, which is not a sub-structure predicted for full length 1G8-14 
structure (compare Figure 4.14A with Figure 4.14B). We performed ITC experiments in 
order to compare the full-length and truncated 1G8-14 constructs in their ability to bind 
eVP35 IID as well as mutant eVP35 IID proteins. Truncated 1G8-14 36-65 bound to 
eVP35 IID WT with a two-site binding mode similar to full-length 1G8-14. However, the 
truncated 1G8-14 36-65 aptamer was unable to bind eVP35 IID R312A (Figure 4.14; 
see Figure 4.14F vs Figure 4.14C). The sensitivity to the eVP35 IID R312A mutation 
was also observed previously for dsRNA binding. We also conducted ITC experiments 
for truncated 1G8-14 1-65 and 1G8-14 36-90 to assess the importance of the 5' 
constant region and 3' constant region, respectively (Figure 4.15). Truncated 1G8-14 1-
65 bound eVP35 IID WT with a two-site binding mode, but similar to truncated 1G8-14 
36-65 was unable to bind eVP35 IID R312A. Additionally, truncated 1G8-14 1-65 
binding to eVP35 IID WT appear to be cooperative and this observation will require 
additional experiments in order to fully explore this behavior (Figure 4.15D-F). 
However, it is evident that there are significant differences between WT and the 1-65 
truncated aptamer. In contrast, truncated 1G8-14 36-90 bound eVP35 IID WT with a 
two-site binding mode similar to full length aptamer and more importantly, this truncated 
aptamer bound eVP35 IID R312A with high affinity (Figure 4.15G-I). Together these 
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data suggest that the variable region of 1G8-14 is important for binding to eVP35 IID, 
but additional contributions from the constant regions are required for the optimal 
aptamer formation. Based on these observations, we used full length aptamers in our 
studies described here.  
 
4.3.6 Aptamers disrupt eVP35 IID-NP interactions and inhibit EBOV 
replication/transcription activity 
 In order to test the utility of the 1G8-14 and 2F11-14 aptamers, we assessed 
their ability to inhibit interactions between eVP35 IID and NP proteins. This interaction is 
important for the function of the filoviral replication complex (Muhlberger et al. 1999; 
Prins et al. 2010). Specifically, residues in the FBP of eVP35 IID are important for 
eVP35 IID-NP interactions and minigenome activity (Figure 4.16A) (Prins et al. 2010). 
Mutation of all four residues in the FBP (eVP35 IID FBP4mut) leads to loss of eVP35 
IID-NP binding in a pulldown assay. In contrast, mutation of residues in the CBP (eVP35 
IID R305A/K309A and eVP35 IID CBP3mut) does not impact eVP35-NP binding. Since 
the FBP appears to be important for both 1G8-14 and 2F11-14 binding, we tested the 
ability of these aptamers to compete with NP for binding to eVP35. Both 1G8-14 and 
2F11-14 aptamers were able to inhibit eVP35 IID-NP complex formation, while dsRNA 
and aptamers 2B3-10 and 2D1-10 are unable to disrupt eVP35 IID-NP interaction 
(Figure 4.16B). Aptamers 2B3-10 and 2D1-10, selected against eVP35 IID CBP3mut, 
are of similar length to 1G8-14 and 2F11-14 aptamers, and they display similar high 
affinity binding to eVP35 IID (Figure 4.16C). Together, our data demonstrate the ability 
of 1G8-14 and 2F11-14 aptamers to specifically disrupt the eVP35-NP interaction. We 
also tested the ability of aptamers 1G8-14 and 2F11-14 to inhibit RNA synthesis in a 
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replication/transcription assay, where the viral replication complex was reconstituted by 
expression of select viral proteins (Muhlberger et al. 1999). Resulting data show that 
1G8-14 and 2F11-14 can antagonize the replication/transcription activity in a dose 
dependent manner (Figure 4.17A). In contrast to these two specific aptamers, 
additional aptamers with similar length and affinity show little to no inhibition, despite all 
six aptamers being present at comparable levels as judged by qRT-PCR (Figure 
4.17B). Altogether, these results demonstrate that 1G8-14 and 2F11-14 aptamers can 
potentially function as competitive inhibitors of the filoviral replication complex by 
disrupting eVP35 IID-NP interactions. However, it is worth noting that the aptamers can 
interact with NP at high protein concentrations (>100 M); thus, it is not clear if 
additional rounds of aptamer optimization with negative selection against NP will be 
necessary prior to use of these aptamers in virally infected cells.  
 
4.3.7 Aptamers differentially recognize closely related filoviral VP35 IID proteins. 
 Filoviral VP35 proteins share high sequence similarity in the IID region (97.6% 
similar, 88.9% identical for RESTV aligned with EBOV; 81.7% similar, 22.9% identical 
for MARV aligned with EBOV) (Figure 4.18C). Therefore, we tested the ability to the 
1G8-14 and 2F11-14 aptamers to differentiate between closely related VP35 proteins. 
The resulting data showed that 1G8-14 aptamer preferentially binds to eVP35 IID 
proteins (EBOV and RESTV VP35 IID proteins) (Figure 4.18A). When binding was 
tested at protein concentrations <1 µM, EBOV and RESTV showed a fractional binding 
>0.6, while <0.1 fractional binding was observed for MARV. In contrast, 2F11-14 
aptamer bound to all three filoviral VP35 IID proteins with >0.5 fractional binding at 
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protein concentrations > 1µM. (Figure 4.18B). The ability of 1G8-14 to differentiate 
between eVP35 IID and MARV VP35 IID proteins is likely due to sequence differences 
between EBOV and MARV VP35 proteins near the CBP. For example, in EBOV VP35 
IID positions 319 and 322 are K319 and R322, respectively, while corresponding 
positions in MARV VP35 IID are T309 and K312 (Figure 4.18C). Thus, it appears that 
the relative sensitivity to different filoviral species is entirely dependent on the relative 
contributions of the different basic patches. 
 
4.4 Conclusions 
In this study, we have identified and characterized two aptamers against eVP35 
IID that bind with low nanomolar affinity using SELEX technology. These aptamers were 
generated by using two targets, eVP35 IID WT and eVP35 IID CBP3mut, with the goal 
of identifying different classes of aptamers that interact with distinct sets of residues 
within filoviral VP35 proteins. Target selection was in large part motivated by available 
structure-function data and our goal was to drive the selection process to different 
functionally important regions of this multifunctional non-enzymatic protein. Based on 
the data described above, our selected aptamers display binding affinities that are 20-
100 fold higher than dsRNA and the 92 nucleotide long random RNA pool that was used 
in the initial SELEX, supporting the specific enrichment of aptamers. From the initial 
groups of aptamers, 1G8-14 and 2F11-14 aptamers were chosen to represent two 
aptamer classes as they bound eVP35 IID with high affinity, disrupted the eVP35IID-NP 
complex, and displayed significant differences at the nucleotide level (~40% difference 
in the aptamer variable region). Biochemical and functional mapping of select aptamers 
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revealed that 1G8-14 and 2F11-14 aptamers bind eVP35 IID primarily through 
interacting with residues from the CBP and the FBP, respectively, although it is 
apparent that additional interactions between eVP35 IID and aptamers are also formed 
due to the highly basic nature of the eVP35 IID surface (Leung et al. 2009). Our ITC 
data revealed two independent binding modes: a high affinity aptamer binding mode 
and a the dsRNA binding mode (Figure 4.9). Each aptamer has a single high affinity 
binding site and multiple dsRNA binding sites. These two binding events are 
energetically independent, at least in the context of eVP35 IID. Interestingly, mutations 
to CBP residues, or key residues for dsRNA binding resulted in the presumable loss of 
the dsRNA binding mode. Therefore, at low eVP35 IID concentrations, we observe the 
high affinity aptamer binding event with a eVP35 IID:aptamer ratio of 1:1. As we 
increase eVP35 IID concentrations, eVP35 IID is able to make additional interactions 
with double stranded regions of the aptamers due to its inherent dsRNA binding 
function, therefore, allowing multiple eVP35 IID proteins to interact with a single 
aptamer.  
This work demonstrates how integrating available structural and functional data 
to tailor SELEX selection can result in aptamers that target different functional regions 
and potentially generate multivalent aptamers. 1G8-14 aptamer was selected against 
eVP35 IID WT and binds primarily to residues in the CBP with additional contacts to the 
FBP region. Despite the fact that the CBP is important for both 1G8-14 aptamer and 
dsRNA binding, there are significant differences in how eVP35 IID binds these two 
ligands. Most notably, a single point mutation within the CBP completely abolishes 
dsRNA binding(Hartman et al. 2004; Leung et al. 2010; Prins et al. 2010). However, 
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single point mutations have only marginal effects on 1G8-14 aptamer binding (Figure 
4.9). In contrast, double and triple mutation of CBP residues significantly affect the 
ability of 1G8-14 aptamer to bind eVP35 IID, which supports the notion that the 
aptamers establish multiple contact sites at the binding interface(s). In addition to the 
CBP, our data shows that mutations within the FBP affect 1G8-14 aptamer binding 
(increases KD,1). Mutation of the FBP along with a single mutation in the CBP region 
abolishes aptamer binding altogether. These results further support the view that 1G8-
14 aptamer recognizes several surfaces across eVP35 IID. In contrast, the main site of 
interaction on eVP35 IID for the 2F11-14 aptamer appears to be near the FBP, with the 
CBP providing additional contact points. Our results clearly suggest that both 1G8-14 
and 2F11-14 aptamers interact with multiple copies of eVP35 IID and therefore there is 
a high potential for these aptamers to inhibit multiple VP35-mediated functions in vivo.  
 In this work, we were able to target the CBP or the FBP of eVP35 IID and show 
that 1G8-14 and 2F11-14 aptamers have distinct binding footprints through biochemical 
mapping. Moreover, we are able to distinguish that the CBP is the primary binding site 
for 1G8-14, while 2F11-14 uses the FBP as its primary binding site. As a multifunctional 
protein, eVP35 IID inhibits IFN responses to viral infection, in part through dsRNA 
sequestration, and supports RNA viral synthesis through structural bridging of NP and 
the viral polymerase L. We have shown that aptamers bind eVP35 IID using multiple 
points of contact, a mode that is distinct from dsRNA binding. Furthermore, aptamers 
can compete with dsRNA for eVP35 IID binding, indicating that aptamers have the 
potential to disrupt the IFN inhibitory function of eVP35. Here we show that aptamers 
disrupt the eVP35-NP interaction and replication/transcription activity, indicating their 
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potential to inhibit eVP35 polymerase cofactor function. It is interesting to note that 
selected aptamers can potentially inhibit both the eVP35 immune suppressor function 
and the polymerase cofactor function. 
Aptamers are well known for their high affinity and specificity against their 
targets. The high specificity of aptamers can be used to distinguish among viral 
subtypes, which is relevant for the development of aptamers against viral proteins. On 
the other hand, aptamers with broad specificity can potentially serve as pan-antivirals. 
One of our selected aptamers, 1G8-14, can distinguish between EBOV and MARV 
VP35 IIDs, binding to EBOV and RESTV VP35 IIDs with KD’s 20-fold lower (at 1 mM 
concentration of protein, see Figure 4.6A) than MARV VP35 IID. The other selected 
aptamer, 2F11-14, can bind EBOV, RESTV, and MARV VP35 IIDs with comparable 
affinities. Thus, we have demonstrated that it is feasible to develop both highly specific 
and pan-antifiloviral aptamers using VP35 as the SELEX target molecule, and our 
success in selecting both highly specific and pan-antifiloviral aptamers indicates that 
there are highly conserved regions of VP35 which are recognized by 2F11-14, as well 
as species unique regions in VP35, which allows differential binding of 1G8-14 to EBOV 
and MARV VP35 IIDs.  
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4.5 Tables 
Table 4.1. Data collection, structure solution, and refinement statistics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Values in parentheses are for the highest resolution shell. 
 
eVP35 IID 
CBP3mut 
eVP35 IID 
FBP4mut 
PDB  4IJE 4IJF 
Data collection  
Space Group P6122 P3221 
Unit cell parameters   
     a, b, c (Å) 81.01, 81.01, 344.89 59.73, 59.73, 67.78 
 (°) 90, 90, 120 90, 90, 120 
Resolution range (Å)* 50 – 1.9 50 – 2.5 
 (1.93 – 1.90) (2.54 – 2.50) 
Unique reflections 54187 (2648) 5063 (226) 
Redundancy 9.1 (5.7) 4.0 (3.9) 
Completeness (%) 99.8(99.5) 99.3(100.0) 
Rmerge(%) 13.0 (0.0) 7.5 (77.1) 
I / I 18.7 (2.3) 16.3 (2.3) 
   
Structure solution and refinement  
Resolution (Å) 33.1 – 1.9 41.1 – 2.5 
 (1.94 – 1.90) (2.60 – 2.51) 
No. of reflections 50451/2559 4421/209 
 (1430/75) (173/9) 
Completeness (%) 93.2 (51) 91.4 (91) 
non-hydrogen atoms 4283 945 
Rwork / Rfree (%) 19.3/22.8 20.0/25.4 
R.m.s. deviations   
     Bond lengths (Å) 0.019 0.01 
     Bond angles (°) 0.880 1.240 
B-factors (Å
2
)   
Protein 
(chain A) 
27.99 49.10 
(chain B) 28.41  
(chain C) 27.79  
(chain D) 29.30  
Water 35.73 50.62 
Ramachandran plot 
outliers (%) 
0 0 
Molprobity score 1.22 1.75 
Molprobity clashscore 4.38 7.97 
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Table 4.2. Measured binding affinities between aptamers and WT or mutant eVP35 IID 
proteins by ITC. 
 1G8-14 2F11-14 
 n1 KD,1(nM) n2 KD,2(nM) n1 KD,1(nM) n2 KD,2(nM) 
WT 1.1±0.1 3.7±0.2 2.7±0.4 1400±500 1.2±0.0
a
 7.1±0.1 5.1±0.1 380±40 
K248A 1.1±0.0
b 
13±1 3.3±0.4 1600±90 1.7±0.0
c 
36±7 5.3±0.1 830±300 
FBP4mut 1.4±0.2 48±30 3.2±0.6 1200±800 - - - - 
R312A 1.2±0.1 83±10 - - 1.4±0.0
d 
52±6 - - 
F239A 1.1±0.0
e 
85±50 - - 1.4±0.0
f 
100±8 - - 
CBP3mut - - - - 1.3±0.1 56±7 - - 
FBP4mut/ 
R312A 
- - - - n.d. n.d. n.d. n.d. 
CBP3mut/ 
K248A 
n.d. n.d. n.d. n.d. 1.6±0.2 180±20 n.d. n.d. 
 
a = 1.2 ± 0.04  e = 1.1 ± 0.02 
b = 1.1 ± 0.03  f = 1.4 ± 0.04 
c = 1.7 ± 0.03  -: no binding 
d = 1.4 ± 0.01  n.d: not determined 
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Table 4.3. Summary of ITC results for aptamers binding to  WT or mutant eVP35 IID proteins. 
 
 dsRNA  1G8-14  2F11-14 
   KD,1 KD,2  KD,1 KD,2 
WT + + + +  + + + + + + + +  + + + + + + + + 
K248A + + + +  + + + + + + + +  + + + + + + + + 
FBP4mut n.d.  + + + + + +  - - 
R312A -  + -  + + + - 
F239A -  + -  + + - 
CBP3mut -  - -  + + + - 
FBP4mut+R312A n.d.  - -  n.d. n.d. 
FBP4mut+F239A n.d.  - -  n.d. n.d. 
CBP3mut+ K248A n.d.  n.d. n.d.  + - 
+ + + + = WT 
     +++ = 5-9 fold decrease in KD 
       ++ = 10-19 fold decrease in KD 
         + = >20 fold decrease in KD 
         -  = no binding 
n.d: not determined 
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4.6 Figures 
 
Figure 4.1 Crystallization optimization of eVP35 IID CBP3mut crystals. (A) 
Representative crystals of eVP35 IID CBP3mut at various stages of crystal optimization. eVP35 
IID CBP3mut crystals suitable for data collection were eventually obtained by hanging-drop 
vapor diffusion method in 2.2M Na/K phosphate (pH 4.5). (B) Representative diffraction pattern 
of the crystals which diffracted to 1.9Å resolution. (C) 2Fo-Fc density map at 1showing the 
experimental electron density (blue mesh) for eVP35 IID CBP3mut centered at residues I320 
(yellow sticks).  
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Figure 4.2. Mutations to the FBP and CBP do not significantly perturb the overall 
structure of eVP35 IID. Ribbon representation of eVP35 IID WT (PDB: 3FKE) 
highlighting residues from the FBP (left) and CBP (right). Ribbon representation of 
eVP35 IID (B) CBP3mut (PDB: 4IJE) and (C) FBP4mut (PDB: 4IJF). (D) PyMol 
alignment of eVP35 IID WT (yellow), CBP3mut (purple), and FBP4mut (cyan) with 
display RMSD values of 0.68 and 0.46 Å, respectively.   
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Figure 4.3. Surface electrostatic analysis of eVP35 IID FBP4mut and CBP3mut. 
Electrostatic surface representation of (A) eVP35IID WT (PDB: 3FKE), (B) CBP3mut 
(PDB: 4IJE), and (C) FBP4mut (PDB: 4IJF) (scale, -10 kT/e to +10 kT/e).  
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Figure 4.4. Enrichment of aptamer populations using SELEX. The progress of in 
vitro selection of aptamers against eVP35 IID WT and eVP35 IID CBP3mut was 
measured by the filter binding assay. The binding curves of RNA populations against 
(A) eVP35 IID WT from rounds 1 and 14 and populations against (B) eVP35 IID 
CBP3mut from rounds 1 and 10 are shown. (C) Representative 1-series aptamers from 
(A) and 2-series aptamers from (B) are shown. Frequency was determined by 
sequencing 96 clones at round 10 and round 14 of SELEX. The number following the 
dash line in the aptamer name (e.g. -10, -14) indicate the round when sequencing was 
done and the aptamers were identified. 
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Figure 4.5. Secondary structure predictions for aptamers 1G8-14 and 2F11-14. 
RNAfold from Vienna package v.2.0 was used to predict the secondary structure for 
1G8-14 and 2F11-14. Results for 1G8-14 are shown as the (A) minimum free energy 
(MFE) structure prediction and (B) base-pairing probabilities using dot plot analysis. 
Results for 2F11-14 are shown as the (A) minimum free energy (MFE) structure 
prediction and (B) base-pairing probabilities using dot plot analysis. Resulting 
secondary structures for the MFE were visualized with the RNA graphics program 
VARNA. Bases depicted in grey represent the 5' and 3' common region of the aptamers.   
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Figure 4.6. CD spectra show that 1G8-14 and 2F11-14 have different secondary 
structures. Left. Ellipicity of 260nm for (A) 1G8-14 and (B) 2F11-14 were collected at 
5˚C (solid line) and 95˚C (dashed line) from 200 to 320 nm. Right. Temperature melting 
of 1G8-14 (black) and 2F11-14 (red) were performed by monitoring the ellipticity at 260 
nm from 5˚C to 95˚C with a 2˚C increment using a 1˚C/min gradient. (C) First derivatives 
of the temperature melts in (A) and (B).   
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Figure 4.7. 1G8-14 and 2F11-14 aptamers bind eVP35 IID WT with high affinity. (A) 
eVP35 IID contains two basic patches. The first basic patch (FBP) contains residues 
K222, R225, K251, and K248 (purple). The central basic patch (CBP) contains residues 
R312, K319, and R322 (cyan). eVP35 IID WT and eVP35 IID CBP3mut were used as 
targets for in vitro selection of 1G8-14 and 2F11-14 aptamers, respectively. Filter 
binding assays were used to assess the ability of (B) eVP35 IID WT and (C) eVP35 IID 
CBP3mut proteins to bind ssRNA, dsRNA, 1G8-14 aptamer, and 2F11-14 aptamer at 
protein concentrations of 0.1 µM (gray), 1 µM (green), and 10 µM (blue). 
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Figure 4.8. Aptamer binding is not affected by the 5’-ppp moeity. ITC raw data and 
corresponding binding isotherms for eVP35 IID WT binding to (A) 5'-PPP 1G8-14 and 
(B) 5'-OH 1G8-14. 
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Figure 4.9. Mutational analysis reveals differences in eVP35 IID-aptamer binding 
sites. Fractional binding of aptamers (A) 1G8-14 and (B) 2F11-14 to eVP35 IID WT and 
mutant proteins measured by filter binding assay. Average fractional binding normalized 
to eVP35 IID WT are from two independent experiments, each with four repeats for 
individual eVP35 IID variants. 
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Figure 4.10. Aptamers compete with dsRNA for eVP35 IID binding, and 1G8-14, 
but not 2F11-14, can compete with 1G8-14 for eVP35 IID binding. Filter binding 
assays were carried out to determine the competition of aptamers and dsRNA for 
binding to eVP35 IID. (A) Binding of 32P-dsRNA to eVP35 IID was competed by 
increasing concentrations of unlabeled 92 nt RNA (■), dsRNA (○), 1G8-14 (▲), or 2F11-
14 (●). (B) Binding of 32P-1G8-14 to eVP35 IID was competed by increasing 
concentrations of dsRNA (○), 1G8-14 (▲), or 2F11-14 (●). (C) Binding of 32P-2F11-14 
and eVP35 IID is competed by increasing concentrations of dsRNA (○), 1G8-14 (▲), or 
2F11-14 (●). 
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Figure 4.11. The CBP is important for high affinity binding of 1G8-14 aptamer to 
eVP35 IID.  ITC raw data and corresponding binding isotherms for 1G8-14 binding to 
eVP35 IID (A) WT, (B) K248A, (C) FBP4mut, (D) R312A,  (E) F239A, (F) CBP3mut, (G) 
FBP4mut+R312A, and (H) FBP4mut+F239A. 
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Figure 4.12. The FBP is important for high affinity binding of 2F11-14 aptamer to eVP35 
IID. ITC raw data and corresponding binding isotherms for 2F11-14 binding to eVP35 IID (A) 
WT, (B) K248A, (C) FBP4mut, (D) CBP3mut, (E) F239A, (F) R312A, and (G) CBP3mut+K248A. 
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Figure 4.13. The minimal binding region of 1G8-14 with eVP35 IID. (A) Partially 
digested 5' or 3' labeled 1G8-14 were selected by filter binding for interactions with 
eVP35 IID. The 5' boundary (left) was determined to start at base 36, and the 3' 
boundary (right) was determined to end at base 65. (B) Secondary structure of the 
protected region, based on the predicted MFE structure (see Figure S4A). Although 
constant regions may be part of the secondary structure under native conditions, these 
additional oligonucleotides are separated under denaturing conditions. (C) The 
nucleotide sequence for 1G8-14 is shown with the constant regions highlighted in grey 
and the variable region highlighted in blue. The location of the minimal sequence of 
1G8-14, nucleotides 36-65, are indicated by the arrows.  
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Figure 4.14. eVP35 IID WT and eVP35 IID R312A show differential binding to 1G8-
14 full length and 1G8-14 truncations. Minimum free energy (MFE) structure 
prediction for (A) 1G8-14 and (D) 1G8-14 36-65, and a schematic of (G) dsRNA. ITC 
raw data and corresponding binding isotherms show that aptamers 1G8-14, 1G8-14 36-
65, and dsRNA binding to eVP35 IID WT (B, E, and H, respectively) or R312A (C, F, 
and I, respectively). Protein concentrations in the syringe were between 90 to 110 µM 
for binding to 1G8-14, and at 200µM for binding to dsRNA. Aptamer/dsRNA 
concentrations in the cell were at 3 to 5 µM, using 5 µcal/sec as the reference power.  
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Figure 4.15. Both the 5' and 3' constant regions of 1G8-14 contributes to high 
affinity binding to eVP35 IID. Minimum free energy (MFE) structure prediction for (A) 
1G8-14, (D) 1G8-14 1-65, and (G) 1G8-14 36-65. ITC raw data and corresponding 
binding isotherms show that aptamers 1G8-14, 1G8-14 1-65, and 1G8-14 36-65 binding 
to eVP35 IID WT (B, E, and H, respectively) or R312A (C, F, and I, respectively). 
Binding to eVP35 IID WT by 1G8-14 1-65 displayed cooperativity (circled in red) which 
we cannot explain.  
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Figure 4.16. 1G8-14 and 2F11-14 aptamers disrupt eVP35 IID-NP interaction. MBP-
His tagged WT or mutant eVP35 IIDs were immobilized on amylose resin and incubated 
with His-tagged NP proteins in the (A) absence or (B) presence of dsRNA or aptamer. 
(A) Lanes 1, 3, 5, 7 are input (I) samples for MBP-His eVP35 IID WT, CBP3mut, 
305A/309A, and FBP4mut, respectively. Lanes 2, 4, 6, and 8 are final bead (FB) 
samples for MBP-His eVP35 IID WT, CBP3mut, 305A/309A, and FBP4mut, 
respectively. (B) Lane 1 shows MBP-His tagged eVP35 IID WT bound to the amylose 
resin. Lane 2 shows the presence of both His-NP and MBP-His eVP35 IID WT, and 
lanes 3-8 are final bead samples for pulldowns done in the absence (lane 3) or 
presence of dsRNA (lanes 4) and aptamers 1G8-14 (lane 5), 2B3-10 (lane 6), 2D1-10 
(lane7) and 2F11-14 (lane 8). (C) eVP35 IID WT binds aptamers 1G8-14, 2B3-10, 2D1-
10, and 2F11-14 at protein concentrations of 1µM (gray), 10µM (black).  
 
  
122 
 
 
Figure 4.17. 1G8-14 and 2F11-14 aptamers inhibit EBOV replication/transcription 
activity in a dose dependent manner. (A) A replication/transcription assay was 
performed in which plasmids encoding the different aptamers (250, 500 ng, left and 
right, respectively) were co-transfected with the plasmids required for minigenome 
replication and transcription. Minigenome reporter activation was expressed as relative 
activity by setting the negative control (without VP35) to a value of 1.  The error bars 
indicate standard deviation of three independent replicates, *p=0.001, **p=0.0005. (B) 
The western blot shows expression of NP and eVP35. (C) Quantitative RT-PCR for 
aptamers mRNA levels using aptamer specific primers was performed. Genome 
equivalent (GEq) copy numbers (Total copies) of aptamers in minigenome assay were 
measured using primer/probes targeting the aptamers. Standards and test samples 
were assayed in triplicate using the CFX96 detection system. Threshold cycle (CT) 
values representing aptamers were used to determine Total Copies. The error bars 
indicate the standard deviation of three independent replicates.  
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Figure 4.18. Aptamers differentially bind to filoviral VP35 IID proteins. eVP35 IID 
from EBOV, RESTV, and MARV were tested in their ability to bind (A) 1G8-14 and (B) 
2F11-14 aptamers at varying protein concentrations shown as fractional binding. (C) 
Sequence alignment of the IID region of VP35 proteins from EBOV, RESTV, and 
MARV. VP35 IID sequences from EBOV (accession no AAD14582), RESTV (accession 
no BAB69004.1), and MARV (accession no CAA78115.1) were aligned using ClustalW. 
Residues highlighted in black are conserved among all three VP35 IID species. 
Residues highlighted in gray are only conserved between two VP35 IID species. 
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Figure 4.19. 1G8-14 and 2F11-14 aptamers have multiple binding modes. VP35 
aptamers display two binding modes that include a single high affinity binding site and 
multiple dsRNA binding sites. At low eVP35 IID WT concentrations or when binding to 
key dsRNA binding mutant R312A, only the high affinity site is occupied. At higher 
concentrations of eVP35 IID WT additional binding events occur via the dsRNA binding 
mode. 
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CHAPTER 5. CONCLUSIONS 
 
 Ebolaviruses are highly pathogenic filoviruses, which infect human and non-
human primates, and are characterized by severe hemorrhagic fever resulting in fatality 
rates as high as 90%. Although filoviral vaccine options are under investigation, no 
approved vaccines are available at this time. Furthermore, other therapeutics such as 
small molecule or drug-like molecules are largely unavailable making the need for 
antivirals that counter filoviral infection a pressing concern. Though multiple factors 
contribute to disease progression, the ability of filoviruses to severely antagonize early 
host innate immune responses while proliferating at high levels in many cell types plays 
an essential role in the high fatality rates associated with filoviral infections.  
 The multifunctional VP35 plays important roles in antagonizing host immune 
responses and in viral replication. Given the essential nature of VP35 to filoviral 
pathogenesis, VP35 is a potentially promising target for antiviral development. However, 
in order to effectively target VP35 it is imperative to biochemically and structurally define 
functionally relevant regions of this protein. Recent structural and functional studies 
from our lab have identified the mechanism by which VP35 binds dsRNA and inhibits 
host immune responses (Leung, Prins et al. 2010). Additionally, these studies revealed 
that there are two highly conserved basic patches termed the first basic patch (FBP) 
and the central basic patch (CBP) located within the C-terminal interferon inhibitory 
domain (IID) of VP35. In order to assess the role of these two basic patches, we 
conducted a series of structural, biochemical, and functional studies. The crystal 
structure of VP35 IID complexed with dsRNA revealed that residues within the CBP 
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make direct contacts with dsRNA, and mutating CBP residues to alanine resulted in loss 
of RNA binding and inhibition of IFN production. Furthermore, these alanine substitution 
mutants resulted in an attenuated recombinant guinea pig adapted ebolavirus that 
conferred protection against WT ebolaviral infection. Work presented in this thesis 
investigates the functionality of the VP35 FBP and demonstrates that, unlike the CBP, 
the FBP is not important for RNA binding or IFN inhibition, but is important for VP35's 
polymerase co-factor function. Current literature in the field has established interactions 
among NP-VP35, NP-VP30, VP35-L, and NP-VP35-L, and these known interactions 
support a model in which VP35 interacts with both NP and L, thus tethering the 
polymerase and its template together (Becker, Rinne et al. 1998; Muhlberger, Lotfering 
et al. 1998; Muhlberger, Weik et al. 1999). Although the exact role of VP35 in replication 
is not well understood, alanine substitution mutations show that the FBP is important for 
the VP35-NP interaction, but not the VP35-L interaction. Furthermore, this work 
provides the first detailed report of critical residues within VP35 that contribute to its 
polymerase co-factor function and defines VP35 residues at the VP35-NP interaction. 
Aside from structurally bridging NP and L together, it is unclear if VP35 performs 
additional functions in the context of the polymerase complex. At present, the molecular 
basis for protein-protein and protein-RNA interactions that establish the polymerase 
complex are poorly defined, but the work presented here, along with additional studies 
on VP35 and the other viral proteins, will be instrumental in developing a 
comprehensive model of the polymerase complex, and provide a framework for 
understanding how the polymerase complex switches between viral transcription and 
replication.  
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 With the functional validation of the FBP and the CBP, and their respective roles 
in viral replication and host immune antagonism, inhibition of VP35 functions through 
targeting these basic patches should not only aid in the development of antivirals, but 
may also provide novel target sites and mechanistic insight into critical VP35-mediated 
functions. In an effort to selectively target the FBP and CBP, we generated RNA 
aptamers targeted against eVP35 IID WT and CBP3mut proteins using SELEX 
technology. Though there are a number of advantages to using aptamers over 
antibodies or small-molecule based strategies, one main advantage is that no prior 
structural information is requires for aptamer development. However, in cases such as 
ours where there are available structural and functional data, the SELEX selection 
strategies can be tailored to enhance aptamer selection to desired functional regions. 
Using eVP35 IID WT and CBP3mut protein as two independent SELEX targets, we 
aimed, and succeeded, in identifying two classes of aptamers which bound to different 
surfaces of VP35. Through these studies we have demonstrated that the aptamers bind 
with high affinity and specificity to eVP35 IID, with aptamer 1G8-14 primarily binding to 
the CBP and aptamer 2F11-14 primarily binding to the FBP. Additional studies revealed 
that selected aptamers, 1G8-14 and 2F11-14, can disrupt the VP35-NP interaction, and 
correspondingly inhibit the functionality of the viral polymerase complex in a 
reconstituted minigenome (MG) assay. The work presented in this thesis, supports the 
development of VP35 specific aptamers, demonstrates how aptamers can be used to 
facilitate the validation of VP35 as an antiviral target, and provides a previously 
unavailable avenue for the development of filoviral antivirals.  
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 In order to consider these aptamers as a serious filoviral therapeutic option, 
additional studies need to be done. In our present work, much effort has been put forth 
to characterize the regions of VP35 which interact with the selected aptamers, 1G8-14 
and 2F11-14, but in moving forward, we need to characterize the aptamers themselves 
and, if need be, improve the pharmacological properties of these aptamers. In contrast 
to antibodies, aptamers often exhibit low immunogenicity and have the ability to be 
chemically modified which allows for enhanced in vivo stability and bioavailability. To 
improve the stability of aptamers, particularly RNA aptamers, in vivo, the aptamers can 
be synthesized with modified bases such as 2′-amino-modified or 2′-fluoro-modified 
pyrimidines, and these modified bases enhance the stability of the RNA aptamers by 
replacing the highly reactive 2'-OH with a less reactive substitute. This in turn increases 
the aptamers half-life and reduces sensitivity to nucleases in serum, and is highly 
beneficial in the development of effective therapeutic aptamers.  
 In addition to enhanced biostability, improving bioavailability is another important 
step in developing these aptamers as therapeutics. In instances such as ours, the 
aptamers need to bind an intracellular viral protein, and therefore, must be taken up 
within an infected cell. Due to their size and negative charge, aptamers have difficulty 
crossing the lipid bilayer. In cultured cells, this dilemma can be overcome by standard 
transfection methods or by expressing the aptamers in the cells. As a therapeutic, 
however, alternative strategies are needed to administer the aptamers and target them 
to the site of infection. Two potential ways to address this are to generate chimeric 
aptamers or to employ an adenoviral expression system. In recent years, aptamers 
have become an increasingly useful tool for delivering RNA molecules such as siRNA to 
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their desired target cells (McNamara, Andrechek et al. 2006). In these experiments, 
RNA aptamers are generated against cell specific markers, and these aptamers are 
used to target their "cargo" to these cells. The feasibility of conjugating aptamers 
together has been investigated in a number of studies, some which are outlined in 
Chapter 3. To adapt this methodology for our purposes, we could fuse 1G8-14 or 2F11-
14 to another aptamer which would be responsible for targeting the chimeric construct 
to desired cells and enhancing its uptake into these cells. A different approach would be 
to use an adenoviral system to express the aptamers within cells. Recombinant 
adenoviral expression systems have become increasingly popular tools to achieve 
transient gene expression in cell based assays and in vivo, and more recently it has 
been shown that adenoviral vectors can effectively deliver shRNA to cells (Crowther, 
Ely et al. 2008). Additionally, an adenoviral expression system provides a key 
advantage in that after systemic administration, adenoviruses exhibit a preferential 
tropism for hepatocytes, a primary location for filoviral replication. In moving forward, 
there are a number of steps that can, and need, to be taken to improve our aptamers 
and provide the filoviral community with the necessary information and reagents to 
accelerate the development of effective therapeutic agents and basic research tools to 
counter filoviral infections.    
 Alternatively, evaluation of the VP35 IID structure revealed a hydrophobic pocket 
near the FBP which could be used as a target for small molecule development. In 
comparison to aptamers, small molecules provide a more traditional approach to 
therapeutic development, and the pharmacological properties which make for ideal 
drug-like molecules are more well defined. Nevertheless, targeting viral proteins from 
134 
 
RNA viruses is often challenging in part due to the propensity of these viruses to 
generate escape mutants. The RNA-dependent polymerases encoded by these viruses 
lacks the proofreading ability of DNA polymerases, therefore, leading to higher error 
rates and the likely hood that a resulting mutation will provide the virus with a selective 
advantage. Escape mutants become especially problematic when applying a small 
molecule approach to drug development.  This is in large part due to the fact that small 
molecule-protein interactions are often supported by  few direct contacts and have little 
buried surface area at the binding interface. In contrast, aptamers can establish multiple 
points of contact with their target, and in our work, we have shown that 1G8-14 and 
2F11-14 binding is largely insensitive to single point mutations. Additionally, the greater 
buried surface area located at the aptamer-protein interface may be advantageous 
when targeting a protein-protein interaction, as small molecules may be unable to 
disrupt enough protein-protein contacts to be effective. Although aptamers and small 
molecules have their own advantages and disadvantages, both are valuable reagents 
that will lead to new and improved therapeutics. In light of the research provided here, 
which establishes VP35 as a promising therapeutic target and identifies the FBP and 
the VP35-NP interface as a region for antiviral development, targeting a pocket near the 
FBP using a small molecule approach may provide an alternative way to therapeutically 
target VP35 and potentially disrupt its role in viral replication.   
 In summary, these studies supports a model where two distinct regions of VP35 
contribute to viral pathogenesis through their polymerase co-factor function and IFN 
inhibition function. Together, this work has further probed the multifunctional VP35, 
providing structural and biochemical insight into the role of the FBP residues, and has 
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identified a potentially new region, or surface, of VP35 to therapeutically target. Through 
the selection and characterization of anti-eVP35 IID aptamers, we have identified 
aptamers which bound with high affinity to VP35, therefore, allowing us to dissect the 
VP35-NP interaction, further confirming the importance of the VP35-NP interaction in 
viral replication, and to provide the initial development of inhibitors targeted against 
VP35. Moreover, these studies demonstrate the feasibility, and potential advantage, of 
using available structural and functional data to design SELEX selection strategies 
which promote aptamer generation against preferred functional regions of a protein. 
These results serve as an initial step in enhancing our understanding of the protein-
protein interactions that establish the EBOV polymerase complex, and establishes a 
framework for targeting VP35 as a potential and effective therapeutic target. 
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